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Abstract 
Introduction 
Non-Hodgkin Lymphoma (NHL) is the most common haematological malignancy encountered in 
adults in South Africa. After diffuse large B-cell lymphoma (DLBCL), Burkitt Lymphoma (BL) 
is the most frequent histological subtype seen. The incidence of NHL including BL has increased 
significantly in the era of the HIV pandemic. Burkitt Lymphoma is an aggressive, high grade B-
cell malignancy, with a very high proliferative index and an aggressive clinical course. In adults, 
almost all the patients with BL, in the South African context are HIV sero-positive, presenting 
with the immunodeficiency related variant of BL. This retrospective study aims to determine the 
demographic, clinical, laboratory and therapeutic outcome of patients with BL, as seen at Chris 
Hani Baragwanath Academic Hospital (CHBAH), over a 10 year period.    
Patients and Methods 
Data was collected retrospectively on the demographic, clinical, and laboratory features, as well 
as the therapeutic interventions and outcome of patients with BL, from the haematology records 
of patients attending the Clinical Haematology Unit, Department of Medicine, CHBAH. 
Descriptive statistical methods were used to analyze the data. The Chi² test was utilized to evaluate 
the significance of observed differences in survival between different categories. Patients were 
considered to be evaluable if they survived longer than 4 weeks.  
Results 
A total of 137 patients were evaluable for the study. There were 75 females and 62 males, with a 
female to male ratio of 1.2:1. The mean age of the study population was 38 years. Ninety eight and 
a half percent of the patients were HIV sero-positive. The overwhelming majority of the patients 
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(98.5%) were black Africans, in keeping with the demographics of the hospital. Most of the 
patients presented with a relatively good performance status (≤ 2). However, in contrast to this, 
the majority of the patients also had advanced stage disease, with bulky disease and extra-nodal 
disease being common. Lymphadenopathy was the most common clinical manifestation, occurring 
in more than 80% of the patients at presentation.  
The most common contributors to morbidity and mortality were disease progression, sepsis (often 
neutropaenic sepsis), and renal dysfunction.  
Discussion 
Females tended to outlive their male counterparts. Age and year of diagnosis did not confer any 
obvious advantage. A favourable performance status was the only demographic factor that showed 
a statistically significant survival advantage at diagnosis.  
The presence of Tuberculosis exposure seemed to confer a worse outcome. Patients on cART 
seemed to survive longer, and those with “B” symptoms tended to perform less favourably. 
Somewhat counterintuitively, the presence of CNS disease and bulk disease seemed to improve 
survival.  
Patients with classical Burkitt Lymphoma fared better than patients with “Intermediate” disease. 
Patients treated with a “Burkitt” protocol performed statistically significantly better than patients 
who were given a standard CHOP-based regimen. The use of Rituximab was shown to be 
beneficial.  
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Conclusion 
The outcomes in this aggressive, high grade, B-cell NHL, occurring almost exclusively in HIV 
sero-positive individuals was poor, with a 2-year survival rate of only 7%. However, with better 
education, a high index of suspicion and expedited referral, timeous workup and staging, better 
attention to and prevention of complications, as well as an intensive multimodality approach to 
therapy, together with early and ongoing use of cART in HIV sero-positive individuals, the outlook 
is likely to be much brighter, with higher sustained response rates and improved long term 
outcomes. This should be the future goals in this devastating malignancy, until novel and 
significantly improved therapy for the disease, becomes a reality.  
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1.0 CHAPTER ONE: LITERATURE REVIEW  
1.1 INTRODUCTION 
Lymphoma refers to a malignant proliferation of lymphoid cells. A vast range of presentations of 
lymphoma exist, arising at different stages of lymphoid maturation.1 
Leukaemia in contrast to lymphoma is a malignancy that primarily involves the blood and bone 
marrow, with spill of abnormal cells in the peripheral blood. Lymphoma may involve the bone 
marrow, but spill into the peripheral blood is generally not a feature. 
Lymphoid malignancies may present as either a lymphoma or a leukaemia or a combination of the 
two. Transformation to an acute leukaemic phase is possible throughout the course of lymphoma.1 
1.2 Classification of Lymphoid Neoplasms 
Different classification systems exist for leukaemias and lymphomas. The International 
Lymphoma Study Group (ILSG) devised a list of lymphoid neoplasms in 1994, in order to achieve 
consensus. This was termed the REAL classification (Revised European American Classification 
of Lymphoid Neoplasms).  This classification looked at all aspects of lymphoid malignancies when 
dividing them into groups, taking into account the morphology, immunophenotype, genotype as 
well as the presenting clinical features and tumour behavior. Each factor was attributed a different 
“weight” in this classification.2 
Other classification systems such as the Kiel Classification previously used in Europe or the 
Working Formulation and Lukes-Collins Classification utilized in the United States of America, 
stratified neoplasms according to their grade and prognostic factors as well as common histological 
and clinical features.2 
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There remained no single “gold standard” method of classifying haematological malignancies.  
Since 1995, the World Health Organization (WHO), has been working towards developing a more 
clinically relevant classification system, based on the updated REAL classification system. 
According to the WHO, there was no need to group neoplasms clinically as treatment protocols 
could be determined by the specific histologic subtype and grade of lymphoma as well as clinical 
prognostic indicators. It was not possible to classify lymphomas based on genetic or molecular 
abnormalities alone, as these are not understood for the majority of these diseases.2 
In 1999, the WHO devised a lymphoma classification system. This has evolved over the years, 
however, the basic premise has remained the same. Under this classification, lymphomas are 
divided into those of B-cell and T- cell origin. These are then further subdivided based on whether 
the lymphoid cells are of precursor or mature/peripheral cell origin.1 
Most commonly, lymphomas and leukaemias arise from B-cells. B-cells contribute to more than 
80-90% of the non-Hodgkin lymphomas (NHL).  
The identification of the “Reed Sternberg” cell as a clonal B-cell of post-germinal centre origin, 
has allowed Hodgkin lymphoma (HL) to be histologically differentiated from NHL.1 
Based on the WHO classification of lymphomas, Burkitt Lymphoma (BL) is categorized and 
classified as a mature/peripheral B-cell neoplasm.1  
1.3 Background and Genetic Basis of Oncogenesis 
Burkitt lymphoma (BL) was first described in Uganda, by Dr Denis Burkitt, who initially thought 
BL to be a sarcoma.3,4 BL is an aggressive malignancy of B-cell origin, arising from the germinal 
center of the lymphoid follicle.  
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At a genetic level, BL affects the c-myc oncogene on chromosome 8. Chromosomal translocations 
involving chromosome 8 and chromosome 14 (most commonly), as well as chromosomes 2 and 
22, result in dysregulation of c-myc, and subsequent oncogenesis.3,5-7 There is no demonstrable 
chromosomal translocation in about ten percent of tumours.8 
Abnormalities of the c-myc oncogene is the genetic hallmark of BL, with the t(8:14) being the 
most common finding. Oncogenesis is thought to occur via a variety of mechanisms including 
alterations of cell cycle regulation, including cellular differentiation and apoptosis as well as 
cellular adhesion and metabolism.9 
Burkitt lymphoma is a highly aggressive malignancy, evidenced by a high rate of proliferation 
(with a Ki-67 proliferation index approaching 100%), and evidence of c-myc dysregulation.3,5,6,8,10  
BL is said to double its cell mass every 24 to 48 hours.8 
There are three clinical variants of BL- endemic, sporadic and immune deficiency related. 3,8 The 
endemic variety was first described by Dennis Burkitt in Central Africa (Uganda) and most 
commonly affects the paediatric population, usually presenting as a jaw mass.5 The sporadic form, 
as it is named, occurs outside of the endemic areas. It presents most commonly in the paediatric 
population with abdominal disease. Non- specific presenting features may be present with 
abdominal disease, ranging from abdominal pain with nausea and vomiting to bowel obstruction 
and gastrointestinal bleeding. Abdominal involvement may mimic acute appendicitis or 
intussusception.9 The third variant has been associated with HIV (immune deficiency related) and 
is highly significant in sub-Saharan Africa due to the high burden of HIV in this part of the 
world.3,11 
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Chronic infection is postulated to increase the risk of developing malignancy. Epstein Barr Virus 
(EBV) has been linked to the endemic form of BL. Epstein Barr Virus (EBV) stimulates 
proliferation of B-cells, potentially causing a malignant transformation. Other chronic infections 
related to BL include HIV (as seen in the immune deficiency related variant), and Malaria. The 
latter has not been proven to be oncogenic, but a link is suspected as endemic BL and Malaria tend 
to occur with a higher prevalence in the same geographical locations.3 
Chronic infections lead to stimulation of B cells (chronic antigenic stimulation), which may result 
in the increased risk of chromosomal translocations in patients with HIV and Malaria. An 
interesting hypothetical corollary is that certain haemoglobinopathies (such as Sickle Cell 
Anaemia) may be protective against BL, as they are protective against Malaria (a concept referred 
to as “balanced polymorphism’’).3 
Environmental agents may increase the risk of developing BL. An example is exposure to a plant 
species, Euphorbiaceae, used in Africa for traditional ceremonies; as well as exposure to Bilharzia 
and other infections, such as Arbovirus.3  
1.4 Epidemiology of Burkitt Lymphoma 
In the United States of America (USA), epidemiological studies report that NHL accounts for 
62.4% of all lymphomas. BL is relatively rare, accounting for 2.4% of all lymphomas.1 
Data from the USA shows that BL typically affects young adults, with a median age at diagnosis 
of 31 years. It has a male preponderance (89%), with 38% of patients presenting at an advanced 
stage of disease (stage III or IV). In the USA, the 5 year survival rate is reported as being 45%.1 
The typical sites of presentation are with peripheral lymphadenopathy (LAD) and an abdominal 
mass.1 The disease has a high affinity for affecting the Central Nervous System (CNS).1 
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Epidemiological data suggests that up to 80% of patients with BL can be cured. In patients who 
have a poor response to chemotherapy, or who relapse; salvage therapy is generally ineffective. 1 
In the Western World, BL appears to have a multimodal incidence.10 Incidence peaks appear to 
differ according to gender, with age peaks at 10, 40 and 70 years in males, and 10 and 70 years in 
females.8 
1.5 The Spectrum of Burkitt Lymphoma 
With the identification of various genetic abnormalities, gene profiling has become increasingly 
important in the diagnosis of BL. Burkitt Lymphoma (BL) may occasionally pose as a difficult to 
distinguish condition, sharing features intermediate between BL and Diffuse Large B Cell 
Lymphoma (DLBCL).1  These entities have been clarified further in the updated 2016 World 
Health Organization classification of lymphoid neoplasms.12 In this updated classification, a new 
category has been included and referred to as High Grade B-cell Lymphoma (HGBL), not 
otherwise specified.12 This refers to patients who have disease intermediate between DLBCL and 
BL, but which lacks a c-myc and BCL2 and/or BCL6 rearrangement.12 
Histologically speaking, a more “mature” progenitor does not necessarily correlate with a less 
aggressively behaving malignancy. Such is the case with the highly aggressive Burkitt Leukaemia, 
the phenotype of which displays a mature follicle cell centre pattern.1 
Lymphomas and lymphoid leukaemias belong to the same spectrum of disease, i.e. Burkitt 
Leukaemia (which is considered the L3 subtype of Acute Lymphoblastic Leukaemia) is included 
in the same spectrum of Burkitt Lymphoma and may be a sequelae of the solid tumour, arise as a 
de novo leukaemia or “coexist” with the solid lymphoma component.2 
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Leukaemic patients tend to have a more aggressive course with higher rates of CNS and extra-
medullary involvement, and with higher levels of lactate dehydrogenase (LDH).13 
Burkitt Lymphoma (BL) has proven itself to be a highly aggressive tumour, and is reported to be 
the most rapidly dividing tumour in man.1 
1.6 Burkitt Lymphoma in the face of the HIV/AIDS epidemic 
According to Statistics South Africa, HIV infection was the third leading cause of death in 2013.14 
In fact, sub-Saharan Africa bears 70% of the global burden of HIV, with South Africa accounting 
for 17.9% of the total HIV burden. South Africa has the third highest rate of HIV infection (after 
Swaziland and Botswana), and women appear to carry a higher virological burden than men.11 
These trends are different to those from the USA, UK and Europe, where most studies on BL have 
been performed and reported. Differing trends with respect to the association between HIV and 
BL, as well as gender differences in terms of incidence, age peaks and response to treatment should 
be expected in the South African setting. 
In the USA, BL is an uncommon form of NHL.5 This is in contrast to Africa, where BL is a 
commonly occurring subtype of NHL.3 BL tends to occur more commonly in males, with a male 
to female ratio of 2.5:1 in one study.8 Males tend to be diagnosed at a later stage, and younger age 
than females.3,5,7,8 
The male predominance is not uniform, with HIV tending to be slightly more common in females, 
and, therefore in areas with a high sero-prevalence rate of HIV, an equal or higher ratio of females 
to males occurs with BL. However, gender differences do not have a significant association with 
increased mortality risk.15 
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A study done at Tygerberg Hospital in South Africa has shown a significant increase in HIV sero-
positive patients presenting with lymphomas of the head and neck. The age at presentation also 
appears to be lower (younger age), with a mean of 35 years. In this study, BL was only seen in 
HIV sero-positive individuals.16 
Burkitt Lymphoma (BL) is an AIDS defining illness.17 The chance of developing BL is 
dramatically increased in the HIV sero- positive population.15 The rate of NHL itself increases with 
worsening immune-suppression (as indicated by a lower CD4 cell count). However, BL shows an 
interesting opposite trend in which very immune suppressed individuals (with CD4 counts lower 
than 50) demonstrate the least incidence of BL. This may indicate that functional CD4 cells are 
required in order for the tumour in BL to arise.10 
The vast majority of lymphomas (approximately 70%) affecting the HIV/AIDS population are 
NHL, and approximately 16% of AIDS related deaths are due to lymphomas.18 The HIV-NHL 
tends to be high grade, aggressive B-cell NHL, the incidence of which continues to increase in the 
current HIV pandemic.19 
The development of combination Anti-Retroviral Therapy (cART) has improved outcomes in this 
group of individuals, where chemotherapy combined with cART shows the best results, despite 
the fact that the diagnosis of immune deficiency related BL itself confers a poor prognosis in the 
era of cART.5,6,18,20 Importantly, and conversely, the improved life expectancy with the 
introduction of cART may increase the incidence of BL.21 
1.7 Staging 
Different staging systems have been employed to define the extent of “spread” of lymphoma. Most 
frequently, the Ann Arbor staging system is used. This staging system may not adequately define 
 
8 
 
the true extent of extra-nodal disease, and as such, an alternative staging system such as the St 
Jude/Murphy staging system, may be superior.9 The features of both these staging systems are 
detailed in the section on “definitions”. 
1.8 The South African Perspective 
A study performed by Sissolak et al, in 2016, at Tygerberg Hospital, Cape Town, has shed some 
light on the spectrum of BL in South Africa. Patients with BL and Lymphoma with intermediate 
features between BL and Diffuse Large B-Cell Lymphoma (DLBCL) were selected from their 
clinical records and laboratory database and studied over a nine year period.22 The study 
concentrated on individuals who were specifically HIV infected. The median CD4 count was 
relatively preserved (188 cell/µl), when compared to international studies. Patients with histology 
showing features intermediate between BL and DLBCL tended to present at an older age and had 
less bone marrow infiltration, as well as lower presenting LDH levels.22  Furthermore, almost 90% 
of patients in the study presented with advanced stage of disease, with the majority of patients 
having Stage IV disease. A quarter of the patients had involvement of the CNS at presentation.22 
In terms of outcomes, the 2-year survival rate was 38%. Mortality was most commonly from sepsis 
(41%), CNS progression of disease or relapse of disease, which jointly accounted for 41% of 
deaths.22 
Combination Anti-Retroviral Therapy (cART) was more easily accessible after 2004 and the study 
at Tygerberg Hospital showed improved survival rates in the cART era.22 Previous 2 year survival 
data, prior to cART availability, was quoted as being only 7%.22 The patients in this study tended 
to be relatively young, with an average age of 38 years at presentation. Twenty one of the 35 study 
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participants (60%) were female (female to male ratio of 1.5:1), which is different to the previously 
mentioned international data.22 
1.9 Clinical and Prognostic Factors 
The clinical hallmark of lymphoma is the presence of significant lymphadenopathy. In addition to 
lymphadenopathy (nodal disease), lymphomas also present with extra-nodal disease (e.g. CNS 
involvement) and less commonly paraneoplastic manifestations. In addition, HL and high grade 
NHL commonly present with “B” symptoms. Burkitt lymphoma generally presents at a younger 
age, with the manifestations as detailed above. Reference has already been made to the endemic, 
sporadic and immune deficiency related variants of BL.  
Lymphomas occur in both Caucasian and non-Caucasian populations.7 However, non-Caucasians 
have been noted to have a poorer outcome, partly due to late presentations, with advanced stage 
disease and more aggressive histology.15,17 
The absence of “B” symptoms and being HIV sero-negative, correlates with a better prognosis.7 
An elevated LDH level is associated with poorer outcome.23 The CNS and Gastrointestinal System 
(GIT) are common sites of extra-nodal disease, with involvement of the CNS conferring an adverse 
prognosis.23 
Up to eleven percent of patients may have occult CNS disease at presentation, based on studies of 
cerebrospinal fluid (CSF). The gold standard for diagnosing CNS disease is cytology of the CSF.  
Flow cytometry has improved diagnostic sensitivity.24 Intra-thecal chemoprophylaxis improves 
CNS disease free survival, but it does not seem to improve the overall mortality rate. Rituximab 
use has also been linked to a decrease in CNS manifestations.24 The CNS also tends to be a 
frequently involved site with disease relapse.21 
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Burkitt lymphoma is an aggressive, potentially curable tumour (particularly with regard to the 
sporadic and endemic varieties of the disease).5,17 Poorer prognoses have been observed in older 
patients, those of non-Caucasian ethnicity, as well as patients presenting at a more advanced stage 
of disease.15,17,23 Elderly patients appear to have a poorer initial performance status,  an increased 
risk of toxicity from chemotherapy, and generally more co-morbidities, leading to a poorer overall 
outcome.6,23 
1.10 Therapy 
Surgical resection was previously utilized as a “debulking” measure in BL. However, this resulted 
in a greater risk of local complications such as bleeding, as well as increased mortality,  secondary 
to septic complications.9 Chemotherapy has proven  to be effective in shrinking tumours and 
surgery as a “debulking” measure has subsequently fallen away from the management of BL.9 
Aggressive treatment can result in complete remission in up to 90 percent of patients, with an 
overall survival approaching 70 percent in adults.9 The last decade has witnessed significant 
improvements in outcomes for BL patients, with more than a quarter of the patients older than 60 
years of age, alive at 5 years after diagnosis.15 
There are multiple treatment approaches. Short and intensive chemotherapeutic regimens appear 
to have more favorable outcomes than a “CHOP” approach.5,20 Optimum treatment appears to 
consist of intensive intravenous chemotherapy, intra-thecal chemoprophylaxis and the use of 
Rituximab.6,15,17,23 Relapse rates have been shown to be lower with regimens consisting of more 
intense chemotherapy.20 
Rituximab is an anti-CD20 monoclonal antibody, and has been shown to improve patient outcomes 
when incorporated into chemotherapy regimens for BL, especially for the older age group.5,6,17  
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Historically, chemotherapeutic regimens have consisted of prolonged and high intensity agents, 
and includes different phases of treatment, viz., induction, consolidation and maintenance 
therapy.9 
Prolonged chemotherapeutic regimens have proven to be less efficacious. Not only are toxic 
effects more pronounced with this approach, but the risk of chemo-resistance is also increased. 
Multiple paediatric chemotherapeutic regimens have been studied and modified for use in adults. 
It was found that regimens consisting of short duration, intensive chemotherapy with minimal 
treatment delays are most efficacious.9 
The different protocols used in the treatment of BL include the French LMB 81, 84, 86 and 89 
regimens. Also important are the German Berlin-Frankfurt-Munster (BFM) protocols, CODOX-
M/IVAC, Stanford regimen, Hyper-CVAD, cancer and leukaemia group B protocol (CALGB), as 
well as the EPOCH and EPOCH-R regimens.9 These protocols tend to incorporate 
cyclophosphamide, methotrexate, bleomycin, vincristine, prednisone and doxorubicin. EPOCH 
regimens include vincristine, doxorubicin, etoposide and cyclophosphamide.21 (See list of 
abbreviations for the details of each of the above regimens).  Treatment tends to be on an inpatient 
basis, at least in the initial phases, due to the highly toxic nature of these regimens.21 
The LMB protocols were among the first to incorporate a “cytoreduction” phase of chemotherapy, 
typically utilizing cyclophosphamide and prednisone, in an attempt to reduce the occurrence of 
Tumour Lysis Syndrome (TLS). Tumour Lysis Syndrome (TLS) is a sequelae of chemotherapy 
and rapid reduction in tumour burden of an intensely highly proliferating or “bulky” malignancy. 
In the LMB protocol, the “cytoreduction” phase is followed initially by two “induction” and two 
“consolidation” phases and then between one to four “maintenance” phases of therapy.9 
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The German multicenter study group also added a “cytoreduction” phase, followed by six cycles 
of chemotherapy including agents such as cyclophosphamide, methotrexate and cytarabine.9 
Approaches as used in the treatment of DLBCL, such as CHOP or R-CHOP, are shown not to be 
beneficial in BL.4 
Stem cell transplantation with a curative intent was shown to have similar cure rates to 
chemotherapy alone, and may actually have a higher overall mortality rate than with chemotherapy 
alone. 9 
Stem cell transplantation in Burkitt Leukaemia patients has also resulted in similar disease free 
survival rates, compared to those treated with chemotherapy alone, and thus does not play a role 
in the current initial management of the leukaemic presentation of BL.13 
Rituximab has been incorporated into multiple treatment regimens (resulting in regimens such as 
R-HyperCVAD or EPOCH-R). Promising outcomes have been demonstrated.9 
The EPOCH-R regimen is a low intensity regimen combining etoposide, doxorubicin, 
cyclophosphamide, vincristine and prednisone with rituximab. A study by Dunleavy et al, 2013, 
has shown that the EPOCH-R regimen is highly effective in the sporadic and HIV associated 
(immune deficiency) forms of BL, seen in adults. This regimen provides evidence that lower 
intensity regimens have benefits of reduced toxicity while achieving high cure rates in specific 
subsets of patients with BL.25 
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1.11 Toxicity 
Toxic effects of treatment range from neurological side effects (including myelitis and peripheral 
neuropathy) to myelosuppression (resulting in a variety of cytopenias, most notably neutropaenia), 
TLS and other miscellaneous effects such as mucositis.9 
There is concern that rituximab, being an anti-CD20 monoclonal antibody would lead to profound 
worsening of immunosuppression, especially in patients who are HIV sero-positive and have a 
pre-existing risk or predisposition for immunosuppression. Studies have shown that the addition 
of Rituximab to treatment protocols does not significantly increase the toxicity risk, including 
sequelae from sepsis. Rather, it was shown that Rituximab improves overall survival as well as 
disease free survival.26 
Initiation of cART and continuation of cART is strongly advocated in the HIV sero-positive 
population. 26 
A specific complication which is worthy of mention is the TLS. Tumour Lysis Syndrome (TLS) 
tends to occur secondary to the rapid release of certain intra-cellular contents, such as is seen 
following the rapid destruction of tumour cells once chemotherapy is initiated. In the presence of 
bulky disease, TLS may develop spontaneously.27 The occurrence of TLS following chemotherapy 
is more common than spontaneous TLS. 
The leak of potassium (hyperkalaemia), phosphorus (hyperphosphataemia) and nucleic acids 
(hyperuricaemia) during tumour cell breakdown may overcome physiological mechanisms and 
result in acute kidney injury (acidosis, renal failure), arrhythmias and neurological complications. 
Tumour Lysis Syndrome (TLS) may be rapidly fatal if not corrected promptly.27 
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Prevention of TLS is an important cornerstone of management in patients with BL. In general, the 
groups at highest risk of developing TLS tend to be patients with haematological malignancies, as 
opposed to other solid tumours, especially if they have bulky disease or a very chemo-sensitive 
tumour, such as is the case in BL and acute leukaemias. 27 
Attention needs to be given to adequate hydration, alkalinization of the urine where indicated, and 
strict monitoring of electrolytes, uric acid and renal function. Uric acid, phosphorous and 
potassium excesses may be managed with pharmaceutical agents aimed at their reduction, such as 
allopurinol or rasburicase (recombinant uricase), phosphate binders and various potassium 
lowering agents.27 Where the TLS is worsening despite the above measures, early recourse to 
haemodialysis may be life-saving.   
1.12 Future prospects 
There remains multiple avenues yet to be explored in developing novel, more targeted therapy for 
BL. Some examples of these potential candidates include DNA methyltransferase inhibitors, 
histone deacetylase inhibitors, antisense oligonucleotides which target c-myc, proteasome 
inhibitors, chain-dependent kinases, selective serotonin reuptake inhibitors (SSRI) as well as 
blockade of EBV related proteins.9 
The role of HIV itself needs to be further explored in the pathogenesis of BL, as the optimal 
prevention and treatment of HIV would lessen the burden of BL.21 There is currently a paucity of 
data regarding the impact of HIV on BL in the South African setting. This study serves as an 
attempt to retrospectively define BL, in patients presenting to a large tertiary care hospital 
(CHBAH), with both a high burden of HIV and a large number of BL patients presenting at a 
single institution. 
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1.13 Conclusion 
A high index of suspicion with early diagnosis and prompt initiation of treatment is of paramount 
importance. Most deaths occur within the first year after diagnosis. After 3 years, the risk of death 
is equivalent to that of the general population. 17 Sepsis is the main contributor to mortality. 
Excellent results are possible with swift initiation of treatment, which includes infection control 
precautions as well as rapid chemotherapy recycling. 23 Attention to supportive care is vital to 
prevent morbidity and mortality, for example preventing TLS by ensuring adequate hydration and 
correcting electrolyte abnormalities as well as hyperuricaemia. 5,6 
Despite having the ability to prognosticate and risk stratify patients, all patients with BL should be 
treated aggressively (with specific therapy) and preferably within the first two days after diagnosis, 
for optimum results.5,6,17 
 
 
 
 
 
 
 
 
 
 
16 
 
2.0 CHAPTER TWO: PATIENTS AND METHODS 
2.1 Objectives 
 To describe the demographics of patients with Burkitt Lymphoma at Chris Hani 
Baragwanath Academic Hospital over a ten year time period (01/01/2005 to 31/12/2014). 
Data to be collected include gender, age, ethnic group, performance status, HIV status, 
LDH level and stage.  
 To describe the spectrum of clinical manifestations of Burkitt Lymphoma seen at Chris 
Hani Baragwanath Academic Hospital (e.g. nodal and extra nodal disease, including bulky 
disease and paraneoplastic manifestations). 
 To correlate differences in demographics, clinical presentation and investigations with 
defined outcomes. 
 To compare outcomes based on chemotherapeutic regimens used, including assessing if 
the addition of Rituximab has had a significant effect on patient outcomes.  
 To describe terminal events or complications where necessary (e.g. sepsis, tumour lysis 
syndrome, relapse). 
 To identify lapses in management which may affect patient outcomes (e.g. prolonged delay 
before initiation of treatment). 
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2.2 Methods 
All patients diagnosed with Burkitt Lymphoma between 1st January 2005 and 31st December 2014 
were included in the study. After ethics clearance (Appendix II) was obtained from the Human 
Research Ethics Committee (HREC), data was collected from patient records available at the 
Clinical Haematology Unit, Department of Medicine at Chris Hani Baragwanath Academic 
Hospital.  
Details such as age, gender, ethnic group, HIV status (and CD4 count), performance status and 
stage at presentation were collected. Laboratory results collected included Full Blood Counts 
(FBC) and differential counts, renal and liver function tests, LDH and uric acid levels, histology, 
cell markers and cytogenetics. Date of diagnosis and date of first treatment were noted. The clinical 
presentation was also recorded, with particular note of nodal verses extra-nodal disease (and the 
sites of these presentations), as well as bulky disease. The course of events in the patients’ files 
were followed and thus, information regarding outcome was recorded, including lymphoma free 
survivors, patients still undergoing treatment, and where necessary the events leading to death or 
major complications.  
The nature of treatment rendered was also reviewed and documented. Whether patients received 
high or palliative doses of intravenous chemotherapy, or whether they received intra-thecal 
chemotherapy as well as radiotherapy was correlated with their outcomes.  
With respect to outcome, patients were classified as “alive”, “deceased” or “lost to follow up” 
depending on their status either at the end of the study period or at the time when such terminal 
events occurred. Survival time was measured in weeks from the date of histological diagnosis to 
the date of study termination or terminal events.  
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Treatment outcomes were classified as complete response- when there was no evidence (clinical 
or laboratory) of residual disease, partial response- when disease remained but was not as extensive 
as at presentation (>50% reduction), or as disease progression- when there was evidence of new 
(progressive) disease. At the last visit seen, patients were recorded as having i) ongoing disease, 
ii) remission, or iii) relapse of disease (please refer to “definitions” section). Events causing death 
or major complications were recorded and classified into larger groups, e.g. sepsis, 
thromboembolic disease, renal failure etc.  
Based on a ten year time period, the study included 137 patients. Patients who survived for less 
than 4 weeks were considered to be “non-evaluable”. The following categories of patients were 
excluded: 
i. Age younger than 13 years 
ii. Patients with insufficient records; and 
iii. Patients in whom the diagnosis was uncertain 
This was a retrospective, observational study; which aimed to describe the demographics of the 
selected patient cohort, identify prognostic factors, and correlate outcomes based on these factors 
as well as the choice of treatment regimen used. 
2.3 Data analysis 
Descriptive statistical methods were used to analyse the data regarding patient demographics. 
Means, medians and ranges were calculated for most categories of data, as appropriate.  
Gender, ethnic group, HIV status and outcomes were expressed as ratios or percentages. The Chi² 
test was used to compare demographics, treatment regimens and laboratory parameters and 
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correlate these factors with patient outcomes. A p-value of less than 0.05 was considered 
statistically significant. 
2.4 Definitions 
 Intravenous infusion: the infusion of a solution into a vein.28 
 Intra-thecal: within the subarachnoid space. 28 
 Chemotherapy: “anti-cancer” medication. Includes oral, topical, intravenous or intra-
thecal. 28 (Certain chemotherapy regimens may be abbreviated in the medical literature 
based on their constituents, e.g. CHOP, referring to Cyclophosphamide, 
Hydroxydaunorubicin, Oncovin, and Prednisone) 
 Performance status: as defined by the Eastern Co-operative Oncology Group 
(ECOG)/Zubrod scale, assesses the ability of patients to continue with activities of daily 
living. Categorized as:29,30 
0. Asymptomatic 
1. Symptomatic but fully ambulatory 
2. Symptomatic, but spends <50% in bed during the day 
3. Symptomatic, but spends>50% of daytime in bed, but not bedbound 
4. Bedbound/bedridden 
5. Death 
 Stage: as defined by the Ann Arbor Staging System 31 : 
I. Disease involving a single lymph node group 
II. Disease involving two or more lymph node groups, on the same side of 
the diaphragm 
III. Nodal involvement on both sides of the diaphragm 
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IV. Diffuse or disseminated involvement of distant sites (e.g. bone marrow, 
liver etc.)  
(Add on ‘A’ or ‘B’ depending on the absence (A) or presence (B) of constitutional 
symptoms) 
The Cotswold Modification of the Ann Arbor Staging System takes into account the 
presence of bulky disease or extranodal extension32: 
 Add ‘X’ if bulk disease, defined as a peripheral mass or lymphadenopathy 
with a diameter > 10 cm, or mediastinal bulk disease, defined as mediastinal 
adenopathy with the widest mediastinal diameter being more than 1/3 of the 
trans-thoracic diameter 
 Add ‘E’ if extranodal extension or single, isolated site of extranodal disease 
 Stage: as defined by the St Jude/Murphy Staging System9: 
I. A single tumour or single anatomic area with the exclusion of the mediastinum 
or abdomen 
II. A single extranodal tumour with regional node involvement or two single 
extranodal tumours on the same side of the diaphragm or primary 
gastrointestinal tumour or two or more nodal areas on the same side of the 
diaphragm. (IIR if completely resected intra-abdominal disease) 
III. Two single extranodal tumours on opposite sides of the diaphragm or all 
primary intra-thoracic tumours or all paraspinal or epidural tumours or all 
extensive primary intra-abdominal disease or two or more nodal areas on 
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opposite sides of the diaphragm (IIIA if localized but not resectable intra-
abdominal disease, IIIB if widespread multi-organ abdominal disease) 
IV. Any of the above with initial CNS and/or bone marrow involvement 
 Constitutional symptoms: symptoms indicating systemic effects of disease. These include 
night sweats (drenching), unexplained fever or significant weight loss (>10% of body 
weight in the preceding six months).28 
 Central lymphadenopathy: considered to be enlargement of the “central lymph nodes”, 
denoted by Waldeyer’s ring, D’espians sign, Pemberton’s sign, Superior Vena Caval 
Syndrome, intra-abdominal lymph nodes and scrotal/testicular involvement in males. 
 Peripheral lymphadenopathy: considered to be enlargement of the peripheral lymph node 
groups, including cervical, axillary, epitrochlear, inguinal, femoral and popliteal 
lymphadenopathy. 
 Remission: abatement of signs and symptoms of a disease. 28 
 Relapse: recurrent manifestations of a disease after an apparent disease-free interval. 28 
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3.0 CHAPTER THREE: RESULTS 
3.1 Demographics 
A total of 164 patients in the Clinical Haematology Unit, Department of Medicine, CHBAH were 
identified as belonging to the spectrum of Burkitt Lymphoma, during the period 01/01/2005 to 
31/12/2014. Twenty seven (27) patients were excluded for reasons as indicated in table 1.1.  
Table 1.1 List of Exclusions 
Study Number Reason for Exclusion 
32 Histology = DLBCL 
38 Histology = DLBCL 
42 Histology = DLBCL 
51 No Biopsy done 
52 Histology = DLBCL 
58 Histology = DLBCL 
59 No Histology found 
61 Histology = DLBCL 
68 Histology = DLBCL 
72 No Histology found 
88 No Histology found 
93 No Histology found 
143 No File Found 
144 Histology = ALL 
145 No Histology found 
146 Histology = DLBCL 
151 No Histology found 
155 No File Found 
156 No File Found 
157 No File Found 
158 No File Found 
159 No File Found 
160 No File Found 
161 No File Found 
162 No File Found 
163 No File Found 
164 No File Found 
DLBCL- Diffuse Large B-cell lymphoma; ALL- Acute lymphoblastic leukaemia  
 
23 
 
Following the exclusions, a total of 137 patients remained for inclusion in the study.  
There was a female preponderance, with females accounting for 54.7% (75/137) of the study 
population, and males 45.3% (62/137) of the study population. The female to male ratio was 1.2:1. 
The mean age at presentation for the patients was 38 years, with a range between 15 and 70 years. 
For females the mean age was 37 years (range 17-60 years), while for males the mean age was 40 
years (range 15-70 years). Refer to figure 1.1 and 1.2:  
 
Figure 1.1 Age Distribution in Females 
 
Figure 1.2 Age Distribution in Males 
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In terms of numbers of patients seen per year, there was a noticeable rise in the number of patients 
with Burkitt Lymphoma/Leukaemia after 2009 (i.e. from 2010). Since then, the numbers have 
remained consistently above 15 patients per year. Refer to figure 1.3: 
 
 
Figure 1.3 Patients Diagnosed per Year 
Interestingly, the incidence seemed higher in the warmer months, with 31.4% (43/137) of the 
patients diagnosed in spring; followed by 27% (37/137) in summer. The colder autumn and winter 
months accounted for 20.4% (28/137) and 21.2% (29/137) of the new diagnoses respectively. 
However, this was not shown to be statistically significant (p value of 0.22). 
On average, approximately 2 weeks elapsed between a tissue diagnosis and referral to the Clinical 
Haematology Unit, Department of Medicine, for treatment. In extreme circumstances, there was a 
lag of over 10 months for one individual, prior to being referred. On the other hand, some patients 
were referred prior to a definitive diagnosis being made. These patients are represented as the 
negative values in figure 1.4 below: 
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Figure 1.4. Referral Lag in Days 
In terms of performance status, most patients were diagnosed with a relatively good performance 
status. Forty six patients (33.6%) were classified as having a performance status of 1. Forty five 
patients (32.8%) had a performance status of 2. Twenty one patients (15.3%) had a performance 
status of 3 and 22 patients (16.1%) had a performance status of 4 at diagnosis. There was 
insufficient data regarding presenting performance status recorded in 3 (2.2%) of the patient 
records. 
In terms of the ethnic group, the vast majority of patients were black (135/137 - 98.5%), with only 
one (0.73%) white and one (0.73%) patient of mixed race, respectively. The marked predominance 
of black patients is generally in keeping with the ethnic distribution of patients at CHBAH. 
Similarly, most patients (135/137 - 98.5%) were HIV sero-positive. Only 2 individuals in the study 
(1.5%) were HIV sero-negative. Most of the HIV sero-positive patients (58 patients, 43%) were 
newly diagnosed with HIV at the time of presenting with Burkitt Lymphoma (BL). Twenty six 
patients (19.3%) were diagnosed with HIV within the year preceding presentation with BL.  
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Sixteen patients (11.9%) were diagnosed with HIV between one and two years prior to presenting 
with BL, 5 patients (3.7%) were diagnosed with HIV between two and five years prior to 
presenting with BL and 16 patients (11.9%) tested HIV sero-positive more than 5 years prior to 
presentation. The exact date of diagnosis of HIV was unknown for 14 patients (10.4%). In terms 
of other chronic infections, as much of 20% (27/137) of the study population had either past or 
current infection with Tuberculosis. Other medical co-morbidities at presentation are represented 
in table 1.2. 
Table 1.2. Co-morbidities 
Co-morbidities Number 
Chronic kidney disease 1 
Pregnancy 5 
Hypertension 5 
Blindness (unrelated to BL) 1 
Hypertension, Dyslipidaemia 1 
 
With respect to patients who were HIV sero-positive, the mean CD4 count was 217/µl (range 3-
929/µl). Forty nine patients (38.9%) had a CD4 count of more than 200/µl; while 77 patients 
(61.1%) had a CD4 count of < 200/µl. Thirty five patients (27.8%) had a CD4 count < 100/µl and 
twenty patients (15.9%) had a CD4 count < 50/µl, respectively. Refer to figure 1.5: 
 
Figure 1.5. Distribution of CD4 Count per number in µl (x106) 
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Seventy eight percent (105/135) of the HIV sero-positive population in the study group were on 
combination Anti-Retroviral Therapy (cART). Of these, most patients were on a first line regimen; 
either a fixed dose combination (FDC) of tenofovir (TDF), emtracitibine (FTC) and efavirenz 
(EFV); or tenofovir, lamivudine (3TC) and efavirenz; or older regimens including stavudine (D4T) 
instead of tenofovir (refer to figure 1.6). About 5% of patients were on second line regimens; and 
one patient had a history of defaulting cART. Thirty four patients (32.4%) were already on cART 
at the time of diagnosis, whereas cART was initiated after diagnosis in 66 patients (62.9%). The 
exact timing of initiation of cART was unknown in 5 of the patients on cART (4.8%). 
 
Figure 1.6. Type of combination Anti-Retroviral Therapy (cART) used 
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3.2 Clinical Presentation 
Constitutional or “B” symptoms (i.e. fever, weight loss and night sweats) were observed in 110 
patients (80.3%). Of these “B” symptoms, weight loss and night sweats occurred most frequently, 
being present in 91 (66.4%) and 74 (54%) of the patients, respectively. Fever was present in 61 
(44.5%) of the patients. 
Fatigue was a commonly occurring secondary symptom, seen in 74 patients (54%). Bleeding was 
reported in 33 (24.1%) of the patients, and 14 patients (10.2%) of the study population reported 
bone pain at diagnosis. Refer to figure 2.1: 
 
Figure 2.1. Symptoms at Presentation 
Lymphadenopathy (LAD) was present in 115 patients (83.9%) at diagnosis. Peripheral LAD was 
observed in 100 patients (73%), whereas central LAD was observed in 42 patients (30.7%). 34 
patients (24.8%) had involvement of both central and peripheral sites of LAD. Of the peripheral 
sites of LAD, the axilla and cervical groups were most commonly involved, as shown in figure 
2.2: 
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Figure 2.2. Distribution of Peripheral Lymphadenopathy (LAD) 
Waldeyer’s ring involvement was noted in 18 patients (13.1%). Intra-thoracic manifestations were 
observed in 7 patients (5.1%). This included lymphadenopathy, mass lesions and pleural effusions. 
Intra-abdominal manifestations were clinically evident in 24 patients (17.5%). Of these, intra-
abdominal masses were observed in 13 patients (9.5%). 
Mass lesions, either nodal or soft tissue masses, were noted in various sites as indicated in table 
2.1. below. Masses in the neck, submandibular and parotid region, femoral area and axillary area 
are likely to represent nodal masses.  
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Table 2.1. Observed Frequency of Mass Lesions 
Other mass Number Percentage 
Neck 16 18.18 
Submandibular 1 1.14 
Jaw 9 10.23 
Breast 12 13.64 
Axillary 20 22.73 
Parotid 3 3.41 
Chest 8 9.09 
Femoral 1 1.14 
Palate 3 3.41 
Thigh 3 3.41 
Facial 5 5.68 
Subcutaneous nodules 1 1.14 
Back 1 1.14 
Cranial (including scalp) 4 4.55 
Abdominal wall 1 1.14 
 
Hepatomegaly was present in 53 patients (38.7%), with splenomegaly evident in 35 patients 
(25.5%). Bleeding manifestations were objectively observed in 21 patients (15.3%).  
Bulk disease (defined as tumour masses >10cm in diameter) was observed in 60 patients (43.8%).  
Peripheral signs such as pallor was present in 42 patients (30.7%), while jaundice was observed in 
16 patients (11.7%). 
Thirty eight patients (27.7%) demonstrated Central Nervous System involvement at presentation. 
The different CNS manifestations are indicated in figure 2.3 below.  
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Figure 2.3. CNS Manifestations 
3.3 Laboratory Investigations 
Blood results at presentation were analysed as a whole, as well as being subdivided based on 
whether patients had leukaemia i.e. spill into the peripheral blood (n=49), no peripheral blood spill  
but significant bone marrow involvement (n=9), or lymphoma without any peripheral blood or 
bone marrow involvement (n=71). 
The mean white cell count (WCC) was 10.3 x109/l for the study population as a whole, with a 
median of 7.9 x109/l and a mode of 3.5 x109/l. The range of white cell count was 2.1 x109/l to 65.8 
x109/l. Leucopenia was regarded as a WCC < 4x109/l. In this regard, 17 patients (12.4%) were 
noted to have leucopenia. Leucocytosis was defined as a WCC > 11x109/l. Twenty eight patients 
(20.4%) had a leukocytosis at presentation.  
Neutropenia was defined as a neutrophil count of < 2x109/l and neutrophilia as > 7.5x109/l. Fifteen 
patients (11%) presented with a neutropenia and 10 patients (7.3%) presented with a neutrophilia.  
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Lymphopenia was defined as a lymphocyte count of < 1x109/l and lymphocytosis as > 4x109/l. 
Lymphopenia was present in 19 patients (13.9%), while 11 patients (8%) presented with a 
lymphocytosis.  
Of the patients in the leukaemic subgroup, 6 (12.2%) had a leucopenia, and 20 (40.8%) had a 
leucocytosis. In the lymphoma group without bone marrow involvement, 9 (12.7%) had a 
leucopenia and 7 (9.9%) had a leucocytosis. In the group with bone marrow involvement, 2 
(22.2%) had a leucopenia and none demonstrated a leucocytosis. Refer to table 3.1: 
Table 3.1. Analysis of the White Cell Count (WCC x 109/l) 
 
The mean haemoglobin level was 10.3g/dl, with a median of 10.5g/dl and a mode of 13.5g/dl. 
Haemoglobin levels ranged between 3.8g/dl and 15.9g/dl. 
In females, anaemia was defined as a haemoglobin level of < 12 g/dl, and 64 females (46.7%) were 
noted to be anaemic. The cutoff for anaemia in males was considered as < 13 g/dl. Forty males 
(29.2%) were anaemic at presentation. No participants presented with polycythaemia. Refer to 
table 3.2:  
 
WCC (Overall) WCC (Overall) Number Percentage WCC (Leukaemic) Number Percentage
Average 10.28 <4 17.00 12.41 <4 6.00 12.24
Median 7.96 >11 28.00 20.44 >11 20.00 40.82
Mode 3.48
Max 65.84 PMN (Overall) Number Percentage WCC (Lymphoma) Number Percentage
Min 2.05 <2 15.00 10.95 <4 9.00 12.68
>7.5 10.00 7.30 >11 7.00 9.86
Lymphocytes (Overall) Number Percentage WCC (Leukaemia/Lymphoma) Number Percentage
<1 19.00 13.87 <4 2.00 22.22
>4 11.00 8.03 >11 0.00 0.00
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Table 3.2. Analysis of Haemoglobin (Hb) Levels (in g/dl) 
  Hb   Hb Number Percentage 
Mean 10.31   <12 (F) 64.00 46.72 
Median 10.50   <13 (M) 40.00 29.20 
Mode 13.50   >16 (F) 0.00   
Max 15.90   >18 (M) 0.00   
Min 3.80         
 
The mean platelet count was found to be 256x109/l at presentation. The median was 254x109/l and 
the mode was 11x109/l, ranging from 3x109/l to 802x109/l. Thrombocytopenia was defined as a 
platelet count < 100x109/l. Thirty three patients (24.1%) were thrombocytopenic. Thrombocytosis 
was defined as a platelet count >450 x109/l. Eighteen patients (13.1%) presented with 
thrombocytosis in this study population. Refer to table 3.3: 
Table 3.3. Analysis of Platelet (PLT) Count (x109/l) 
  PLTS   PLTS Number Percentage 
Mean 256.23   <100 33.00 24.09 
Median 254.00   >450 18.00 13.14 
Mode 11.00         
Max 802.00         
Min 3.00         
The biochemistry results are summarized in tables 3.4 and 3.5, as indicated below: 
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Table 3.4. Biochemistry Results 
Na- Sodium; K- Potassium; Creat- Creatinine; Ca- Calcium; Po4- Phosphate; LDH- Lactate Dehydrogenase; B2mg- Beta-2 
microglobulin; UA- uric acid 
The biochemistry results (urea and electrolytes, calcium, magnesium, phosphate, LDH, Beta-2 
microglobulin and uric acid) are shown in table 3.4 while in table 3.5 and table 3.6 there is a 
breakdown of the parameters in the 3 different groups i.e. leukaemia, lymphoma and 
leukaemia/lymphoma.  
With regard to the calcium levels, hypocalcaemia is rare (1 patient - 0.73%), while hypercalaemia 
(defined as a calcium level above 2.56 mmol/l) was noted in 27 patients (19.71%).  
The normal serum LDH level at CHBAH during the period of study was 140-280 U/L. Not 
surprisingly, 94 patients (68.61%) had elevated levels of LDH, in keeping with more advanced 
and bulky disease.  
Of note, hyperkalaemia and hypokalaemia was seen in an equal number of patients, i.e. 19 patients 
(13.87%) in each group. Renal dysfunction (raised urea > 7.1 and raised creatinine >107) was 
noted in 24.09% (33 patients) and 35.04% (48 patients), respectively.  
 
 
 
Na K Urea Creat Ca PO4 LDH B2mg UA
Mean 136.40 4.25 7.92 115.69 2.49 1.28 2201.87 13.00 0.52
Median 136 4.15 5 70 2.37 1.16 1171.00 4.50 0.42
Mode 136 4.1 3.3 66 2.24 1.10 2000.00 3.10 0.89
Range 114 - 149 2 - 6.9 1.6 - 34.2 8 - 713 1.82 - 4.65 0.06 - 3.81 186 - 20000 1.5 - 316 0.11 - 1.9
 
35 
 
Table 3.5 Laboratory Results (Urea and Electrolytes)  
K-Potassium; Creat- Creatinine 
Based on our local laboratory, a Beta-2 microglobulin level of more than 4 mg/L during the period 
of study, was considered to be elevated. Overall, 25 patients (18.25%) had elevated levels. 
However, renal dysfunction may contribute to elevated Beta-2 microglobulin levels. Lastly, 
hyperuricaemia was seen in 46 patients (33.6%). 
All Number Percentage All Number Percentage All Number Percentage
K <3.5 19.00 13.87 Urea <2.5 9.00 6.57 Creat <74 70.00 51.09
K >5.0 19.00 13.87 Urea >7.1 48.00 35.04 Creat >107 33.00 24.09
Leukaemia Number Percentage Leukaemia Number Percentage Leukaemia Number Percentage
K <3.5 9.00 12.68 Urea <2.5 1.00 2.04 Creat <74 16.00 32.65
K >5.0 9.00 12.68 Urea >7.1 30.00 61.22 Creat >107 22.00 44.90
Lymphoma Number Percentage Lymphoma Number Percentage Lymphoma Number Percentage
K <3.5 8.00 11.27 Urea <2.5 7.00 9.86 Creat <74 48.00 67.61
K >5.0 7.00 9.86 Urea >7.1 13.00 18.31 Creat >107 10.00 14.08
Leukaemia/Lymphoma Number Percentage Leukaemia/Lymphoma Number Percentage Leukaemia/Lymphoma Number Percentage
K <3.5 1.00 11.11 Urea <2.5 1.00 11.11 Creat <74 4.00 44.44
K >5.0 2.00 22.22 Urea >7.1 2.00 22.22 Creat >107 0.00 0.00
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Table 3.6 Laboratory Results (other)
Leuk/Lymph- Leukaemia/Lymphoma; po4- Phosphate; LDH- Lactate Dehydrogenase; B2Mg- Beta-2 microglobulin 
HIV infection and details of CD4 counts have been previously described in the demographics 
section. The average viral load was 2 173 340 copies/ml; with a median of 67 940 copies/ml and 
a mode of 10 000 000 copies/ml. The viral load ranged between 23 copies/ml and 67 000 000 
copies/ml. 
Seven out of 52 patients (13.5%) screened for viral hepatitis were positive.  
The results of liver function tests is shown in table 3.7 and table 3.8 below: 
Table 3.7 Liver Function Tests 
  Bilirubin 
Conjugated 
Bilirubin 
Total 
Protein Albumin Globulin ALP GGT ALT AST 
Mean 24.33 18.38 74.34 33.26 33.63 215.53 206.14 47.01 72.80 
Median 6.00 3.00 74.50 34.00 37.50 117.00 76.00 27.00 46.00 
Mode 4.00 2.00 84.00 31.00 0.00 66.00 35.00 28.00 25.00 
Max 346.00 377.00 106.00 72.00 76.00 1664.00 2574.00 342.00 400.00 
Min 2.00 1.00 40.00 5.00 0.00 34.00 8.00 7.00 10.00 
ALP- Alkaline Phosphatase; GGT- Gamma Glutamyl Transferase; ALT- Alanine Transaminase; AST- Aspartate Transaminase 
All Number Percentage All Number Percentage All Number Percentage All Number Percentage
Calcium <2.05 1.00 0.73 po4 <2.5 112.00 81.75 LDH <140 1.00 0.73 B2Mg>4 25.00 18.25
Calcium >2.56 27.00 19.71 po4 >4.5 0.00 0.00 LDH >280 94.00 68.61
Leukaemia Number Percentage Leukaemia Number Percentage Leukaemia Number Percentage Leukaemia Number Percentage
Calcium <2.05 1.00 2.04 po4 <2.5 36.00 73.47 LDH <140 1.00 2.04 B2Mg>4 11.00 22.45
Calcium >2.56 21.00 42.86 po4 >4.5 0.00 0.00 LDH >280 31.00 63.27
Lymphoma Number Percentage Lymphoma Number Percentage Lymphoma Number Percentage Lymphoma Number Percentage
Calcium <2.05 0.00 0.00 po4 <2.5 65.00 91.55 LDH <140 0.00 0.00 B2Mg>4 10.00 14.08
Calcium >2.56 4.00 5.63 po4 >4.5 0.00 0.00 LDH >280 54.00 76.06
Leuk/Lymph Number Percentage Leuk/Lymph Number Percentage Leuk/Lymph Number Percentage Leuk/Lymph Number Percentage
Calcium <2.05 0.00 0.00 po4 <2.5 9.00 100.00 LDH <140 0.00 0.00 B2Mg>4 2.00 22.22
Calcium >2.56 1.00 11.11 po4 >4.5 0.00 0.00 LDH >280 8.00 88.89
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The normal albumin levels were regarded as being between 35 g/l and 52 g/l. Overall, 65 patients 
(47.45%) had hypoalbuminaemia, whereas only one patient had values higher than the expected 
normal range.  Refer to table 3.8: 
Table 3.8 Albumin Levels (g/l) 
All Number Percentage 
Alb <35 65.00 47.45 
Alb >52 1.00 0.73 
      
Leuk Number Percentage 
Alb <35 25.00 51.02 
Alb >52 0.00 0.00 
      
Lymph Number Percentage 
Alb <35 34.00 47.89 
Alb >52 1.00 1.41 
      
Spill Number Percentage 
Alb <35 3.00 33.33 
Alb >52 0.00 0.00 
Alb- Albumin 
3.4 Staging 
Seventy one patients (51.8%) had no demonstrable involvement of the bone marrow, while 9 of 
the patients (6.6%) had involvement of the bone marrow without spill into the peripheral blood, 
and 49 of the patients (35.8%) presented in a leukaemic phase. Bone marrow biopsy results were 
unknown in 8 of the patients (5.8%).  
Most of the patients presented with advanced stage disease (stage III and IV), both clinically and 
radiologically. Seventy six of the patients (55.5%) were classified as stage IVB at presentation. 
The second most frequently observed stage at presentation was stage IIB, accounting for 22 of 
the patients (16.1%), followed by stage IB (14 patients, 10.2%) and IIIB (12 patients, 8.8%). 
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Patients without “B” symptoms were less commonly seen. Stage IIA accounted for 6 of the 
patients (4.4%), while 2 of the patients (1.5%) presented with stage IA and stage IIIA disease. 
There were no patients with stage IVA disease. Figure 4.1 below demonstrates the breakdown of 
patients according to clinical stage. 
 
Figure 4.1 Clinical Stage 
Radiologically, stage IV disease was again most frequently observed, accounting for 75 of the 
patients (54.7%). Stage II disease accounted for 13 patients (9.5%), followed by stage III with 8 
patients (5.8%) and stage I with 1 patient (0.7%). This is represented in figure. 4.2 below: 
 
Figure 4.2 Radiological Stage 
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3.5 Histology 
Tissue diagnosis was most commonly achieved on biopsies of the various nodal masses or on bone 
marrow aspirate and trephine (BMAT) biopsies. The sites of the biopsies with their frequencies 
are shown in table 5.1 below: 
Table 5.1 Biopsy Sites for Histological Diagnosis 
Biopsy site Absolute Percentage 
Lymph node biopsy 50 36.50 
BMAT 38 27.74 
Bowel biopsy 10 7.30 
Unknown 8 5.84 
Chest mass 5 3.65 
Liver biopsy 4 2.92 
Breast mass 4 2.92 
Gastric biopsy 4 2.92 
Ovarian mass 3 2.19 
Oral mass 3 2.19 
Anal mass 2 1.46 
Postnasal space mass 1 0.73 
Peripheral blood 1 0.73 
Cavernous sinus mass 1 0.73 
Paraspinal mass 1 0.73 
Brain biopsy 1 0.73 
Orchidectomy 1 0.73 
Total 137 100.00 
BMAT- Bone Marrow Aspirate and Trephine 
Eighty four percent (84%) of histology samples revealed a diffuse pattern of infiltration, 
predominantly of intermediate sized cells (84%), with a typically high rate of proliferation, as 
evidenced by the very high Ki-67 proliferation index. The average Ki-67 was 96.8%. Refer to table 
5.2 and 5.3. 
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Table 5.2 Pattern of Infiltration and Cell Size 
Pattern of infiltration Number Percentage 
Diffuse 115 83.94 
Focal/nodular 1 0.73 
Interstitial 0 0.00 
Unknown 21 15.33 
Total 137 100 
      
Cell Size Number Percentage 
Small 10 7.30 
Intermediate 115 83.94 
Large 56 40.88 
Mixed 54 39.42 
Unknown 13 9.49 
 
In terms of other markers, CD20 and CD10 were positive in >80% of the specimens, (i.e. 87% and 
81%, respectively). BCL6 was positive in 66% of the patients (see table 5.3 below). 
Table 5.3 Cell Markers 
Markers Positive Negative Unknown Percent Positive 
CD20 119 1 17 86.86 
CD10 111 1 25 81.02 
MUM1 41 40 56 29.93 
BCL6 90 9 38 65.69 
BCL2 37 51 49 27.01 
Ki67 118 0 19 86.13 
 
In patients where Fluorescence in situ Hybridization (FISH) was performed to ascertain 
chromosomal abnormalities, 42% were positive for the t(8;14) translocation. One patient was 
positive for t(8;2). No patients were positive for t(8;22). The c-myc rearrangement was observed 
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in 10%, overlapping with the translocations mentioned above. These results are summarized in 
table 5.4 below: 
Table 5.4 FISH Results 
Translocation Positive Negative Unknown Percent Positive 
t(8;14) 57 41 39 41.61 
t(8;2) 1 0 136 0.73 
t(8;22) 0 1 136 0.00 
c-myc 14 15 108 10.22 
Other: 4     2.92 
extra copy c-myc 2 1.46 
trisomy of chromosome 8 and 14 1 0.73 
monosomy of chromosome 8 1 0.73 
 
On in depth review of the histology samples, 87.6% (120) of the patients studied were deemed to 
be harboring a “Burkitt” lymphoma spectrum disorder; whereas 12.4% (absolute number 17) of 
patients had histology deemed “intermediate” between Burkitt Lymphoma and Diffuse Large B 
Cell Lymphoma.  
3.6 Therapy 
In addition to supportive care, patients received specific therapy, with combination chemotherapy 
being the mainstay of treatment. Patients received either a ‘Burkitt” protocol (modified “CHBAH-
based” chemotherapy regimen, formulated on the backbone of existing regimens), or a CHOP 
approach (see Appendix III and definitions) 
Ninety four patients (69%) received the “Burkitt” protocol; whereas 32 patients (23%) received 
CHOP. Two patients (1.5%) received an alternative chemotherapeutic regimen.   
 
42 
 
Of the patients whose histology was most in keeping with BL, 25 (20.8%), received CHOP 
whereas 86 (71.7%) received a “Burkitt” protocol. The mean number of cycles of CHOP received 
was 4.7, ranging between 1 and 13 cycles, with a median of 3.5 cycles.  
Of the patients whose histology was “intermediate”, 7 (41.2%) received CHOP and 8 (47.1%) 
received a “Burkitt” protocol. The mean number of cycles used of the “Burkitt” protocol was 5, 
usually ranging between 1 and 12 cycles. Three patients received additional cycles of maintenance 
chemotherapy in the “Burkitt” protocol totaling a range between 13 and 16 cycles. 
Rituximab was used in the management of 50 patients (36.5%). Forty four (88%) of these patients 
had classical BL, while the remaining 6 (12%), had features “intermediate” between BL and 
DLBCL.  
Intra-thecal chemotherapy was utilized in 82 patients (60%). Seventy four (90.2%) of these 
patients had BL and 8 (9.8%) were classified as having an “intermediate” spectrum of disease. The 
mean number of cycles of intra-thecal chemotherapy received was 5, ranging between 1 and 13. 
Radiation was used in 25 patients (18%). Twenty one (84%) of these patients had BL, while 4 
(16%) had an “intermediate” form of disease. The various types of radiation employed are 
tabulated in table 6.1 below: 
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Table 6.1 Sites of Irradiation 
  Number Percentage 
Cranial 5 20 
Spinal 2 8 
Cranio-spinal 3 12 
Neck 2 8 
Axillary 5 20 
Spinal and axillary 1 4 
Para-spinal 1 4 
Chest 2 8 
Pelvis 1 4 
Thigh 1 4 
Unknown 2 8 
Total 25 100 
A variety of supportive measures/therapies were offered to the patients in the study (see table 6.2). 
Table 6.2 Supportive Therapeutic Measures 
  Number Percentage 
Antibiotics 104 75.91 
Blood Products 75 54.74 
Growth Factors 36 26.28 
Anticoagulants 21 15.33 
Bisphosphonates 3 2.19 
Dialysis 10 7.30 
Other     
Inotropes 1 4.35 
PTC 3 13.04 
TB treatment 2 8.70 
Tracheostomy 1 4.35 
Psychology 
intervention 1 4.35 
Intubation 1 4.35 
TB prophylaxis 5 21.74 
IV fluids 4 17.39 
Abscess drainage 1 4.35 
Physiotherapy 2 8.70 
Polygam 1 4.35 
Antihypertensives 1 4.35 
Total (Other) 23  
   
PTC- Percutaneous Transhepatic Cholangiogram 
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3.7 Complications 
Sepsis was by far the most commonly noted complication, followed by haematological and CNS 
manifestations. The graph below illustrates the distribution of complications:
 
Figure 7.1 Broad Categories of Complications 
As mentioned above, sepsis was the most frequent complication and was observed 126 times 
(36.3% of complications). Neutropaenic sepsis and pneumonia were amongst the major 
contributors in this category. Refer to table 7.1 below: 
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Table 7.1 Septic Manifestations  
Type of Sepsis Number 
Sepsis- undefined 35 
Neutropaenic sepsis 26 
Pneumonia 23 
Meningitis 7 
Gastroenteritis 6 
Abscess 4 
Upper respiratory tract infection 4 
Herpes 3 
Septic shock 3 
TB 5 
Wound sepsis 3 
Aspergillosis 1 
Brain abscess 1 
Cholangitis 1 
Colitis 1 
Genital warts and phimosis 1 
Liver abscesses 1 
Tonsillitis 1 
TB- Tuberculosis 
Bleeding was observed in 7 patients (2%). Other haematological manifestations (either secondary 
to treatment or disease related) and Central Nervous System disease accounted for 14% each of 
the complications, respectively.  
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Table 7.2 Haematological and CNS Manifestations 
Haematological Number CNS Number 
Myelosuppression 26 CNS disease progression 21 
Anaemia 2 Neuropathy 8 
DIC 2 Seizures 6 
Neutropaenia 21 Myelopathy 3 
    Paraplegia 3 
    Subdural haemorrhage 3 
    Brachial plexus palsy 2 
    Psychosis 2 
    Blindness 1 
    Major depression 1 
    Monoplegia 1 
Total 51  51 
DIC- Disseminated Intravascular Coagulopathy; CNS- Central Nervous System 
Renal dysfunction was observed 39 times (11.2% of the complications). This was further 
categorized in table 7.3 as follows: 
Table 7.3 Causes of Renal Dysfunction 
Complication Number Percentage 
Tumour Lysis Syndrome 16 41 
Renal Failure:   
-Prerenal 3 8 
-Renal 19 49 
-Postrenal (Obstructive Uropathy) 1 3 
 
Venous thromboembolic disease (VTED) was observed 23 times (6.6% of complications). 
Thrombosis was observed at multiple sites, as tabulated below (see table 7.4): 
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Table 7.4 Sites of Venous Thrombosis 
Type VTED Number 
DVT 12 
PTED 3 
Renal vein thrombosis 2 
Brachial vein thrombosis 1 
IJV Thrombosis 1 
IVC thrombosis 1 
Portal vein thrombosis 1 
Splenic vein thrombosis 1 
Transverse sinus thrombosis 1 
VTED- Venous Thromboembolic disease; DVT- Deep Venous Thrombosis; PTED- Pulmonary Thromboembolic Disease 
Gastro-intestinal or metabolic complications accounted for a further 21 complications (6.1%). Of 
these complications, obstructive jaundice was most frequently encountered, as shown in table 7.5: 
Table 7.5 GIT/Metabolic Manifestations 
GIT/Metabolic Number 
Obstructive jaundice 4 
DILI 2 
Hypoglycaemia 2 
Liver failure 2 
Steroid induced hyperglycaemia 2 
Steroid induced hypertension 2 
Biliary obstruction 1 
Bowel perforation 1 
Perforated ulcer 1 
Diabetic ketoacidosis 1 
Perianal disease 1 
Other 2 
DILI- Drug Induced Liver Injury 
Respiratory complications accounted for 9 complications (2.6%). Five patients developed upper 
airway obstruction and two had respiratory failure of unknown cause. One patient sustained an 
iatrogenic pneumothorax, while another patient developed pulmonary oedema.  
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Some of the less commonly encountered complications are shown in table 7.6 below: 
Table 7.6 Bleeding, Compliance, Treatment and Miscellaneous Complications 
Bleeding Number Compliance Issues Number 
Per Vaginal 3 Defaulted chemotherapy 3 
Over warfarinization 2 Refused hospital treatment 2 
Bleed (generalized) 1 Defaulted cART 1 
Bleeding gums 1 cART virological failure 1 
        
Treatment Related Number Miscellaneous Number 
Alopecia 1 Sacral bedsores 1 
Cardiomyopathy 1 Pregnancy 1 
Mucositis 1 Pericardial Tamponade 1 
Neutropaenic enterocolitis 1 Neck of femur fracture 1 
Persistent vomiting 1 Carcinoma in situ (eye) 1 
Post radiation dermatitis 1 
Foetal distress (pregnant 
patient) 1 
Urethral injury 1 Haemorrhoids 1 
 
Compressive features or mass effect was noted in 1% of the patients with complications. There 
were 4 patients, one each with lymphoedema, proptosis, Superior Vena Caval (SVC) obstruction 
and “mass effect of tumour”. 
3.8 Outcomes 
Response to therapy was divided into an “initial response”, generally taken after the first course of 
chemotherapy, an “interim response” noted during the course of treatment and a “last response”, 
noted at the last visit.  
Ninety two patients (67.2%) had at least a partial response to initial therapy, one patient (0.73%) 
was in remission and 3 (2.2%) had ongoing disease or disease progression. In the interim phase, 
44 (32.1%) patients exhibited a partial response, 11 (8%) patients were in remission, and 22 
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patients (16.1%) had ongoing disease or disease progression. At the last interval, 15 patients (11%) 
had a partial response, 21 patients (15.3%) were in remission, and 97 patients (70.8%) were 
classified as having ongoing disease/progression. The category of disease progression includes 
patients who had demised over the course of therapy.  
Eight patients (5.9%) were noted to have relapsed disease during the course of this study. One of 
these patients was subsequently lost to follow up. All the other patients with relapse of disease 
have subsequently demised. Table 8.1 below summarizes the site and timing of the relapse within 
the chemotherapeutic regimen as well as what measures were taken in an attempt to manage the 
relapse. 
Table 8.1 Relapsed Disease 
 
For the patients who received the “Burkitt” protocol, the following was noted: 
 a. 90 patients (95.7%) did not complete the full course of therapy. 
 b. 4 patients (4.3%) completed maintenance therapy. All are alive and in complete 
                remission (survival 1.7 to 4.5 years). 
 c. 67 patients (71.3%) died, prior to institution of maintenance chemotherapy. 
Study Number Site of Relapse Timing of Relapse within Burkitt Protocol Management Outcome
18 Neck Mass Prior to maintenance Radiation Lost to Follow Up
57 Leukaemia N/A (after cycle 5 CHOP) Chemotherapy Demised
65 CNS N/A (after cycle 1 CHOP) Reinduction Demised
82 Axillary Mass During Maintenance Reinduction Demised
85 Leukaemia Alternative chemotherapy regimen Chemotherapy Demised
103 Breast Mass During Maintenance Radiation planned Demised
117 Axillary Mass During Maintenance Reinduction and Radiation Demised
152 Axillary Mass  N/A (after cycle 2 CHOP) Alternate Chemotherapy Demised
(N/A if patient not on Burkitt Protocol)
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For the whole study population, 96 patients (70.1%) died, 17 patients (12.4%) are alive and 24 
patients (17.5%) are lost to follow up (LTFU) (see figure 8.1 below). 
 
 
Figure 8.1 Outcome of the Study Population 
The overall mean survival time was 32 weeks, with a range of 0 to 380 weeks. The overall median 
survival was 12 weeks and the mode was 2 weeks. These figures suggest a very high mortality rate 
within the first 4 weeks of diagnosis. If we consider patients who survived less than a month; and 
those who received no therapy as “non-evaluable”, then the survival trends are as follows, in table 
8.2: 
 
 
 
 
Outcome
Alive Deceased LTFU
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Table 8.2 Survival Times 
Evaluable Number Percentage  Mean (weeks) 
Survival > 4 weeks 103 75.18 42 
Survival > 8 weeks 89 64.96 48 
        
Non-Evaluable Number Percentage Median (weeks) 
Survival < 4 weeks 34 24.82 23 
Survival < 8 weeks 48 35.04 27 
 
For patients who survived longer than 4 weeks, the mean survival time was 42 weeks. For patients 
who survived longer than 8 weeks, the mean survival time was 48 weeks.  
Survival trends at annual intervals from year one to year five equated to 17%, 7%, 4%, 2% and 
1% respectively. The absolute number of patients alive after each year is represented in figure 8.2 
below: 
 
Figure 8.2 Survival Trends per Year 
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In terms of causes of death, 13 main categories were identified. Some patients had multiple 
contributors to mortality, for example sepsis and renal failure. Of these categories, disease 
progression was the most common contributor to mortality, accounting for 66 deaths (37.1% of all 
contributors to mortality). This was closely followed by sepsis, which contributed to 64 deaths 
(36%). Renal failure (not due to tumour lysis syndrome) accounted for 13 deaths (7.3%). Tumour 
lysis syndrome contributed to a further 7 deaths (3.9%). Pulmonary embolism was the culprit in 
13 patients (7.3%). Please see figure 8.3. Other causes such as bone marrow failure, bleeding, liver 
failure and DIC accounted for a total of 11 deaths (6.2%). 
Neuroglycopenia, subdural haemorrhage, Acute Respiratory Distress Syndrome (ARDS) and 
congestive cardiac failure each accounted for 1 (0.6%) death, respectively. 
 
Figure 8.3 Top Five Contributors to Mortality 
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3.9 Prognostic Factors 
In an attempt to identify the prognostic factors, comparisons were made between different groups. 
These have demonstrated some subtle differences, however many of them are not considered 
statistically different; if we consider a p-value of less than 0.05 to be significant. Each factor was 
considered at 4 weeks and at 8 weeks.  
The first demographic to be considered was gender. After 4 weeks; 81% of females were still alive; 
and 68% of males were alive.  After 8 weeks, 70% of females were alive, and 58% of males were 
alive. This meant an overall survival of 75% at 4 weeks and 65% at 8 weeks. The gender difference 
observed was not statistically significant (p = 0.07 at 4 weeks and 0.14 at 8 weeks). Refer to table 
9.1 below: 
Table 9.1 Gender Differences in Survival 
Alive after 4 weeks    Alive after 8 weeks     
                
 Male Female Total  Male Female Total 
Alive 42 60 102 Alive 36 52 88 
Deceased 20 14 34 Deceased 26 22 48 
Percentage Alive 67.7 81.1 75 Percentage Alive 58.1 70.3 64.7 
Total 62 74 136 Total 62 74 136 
 
The next demographic to be considered as a prognostic factor was age. This was divided into 6 
age groups, i.e. <20 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years and 60-69 years. 
The percentage of patients alive in each category respectively at 4 weeks was 100%, 63%, 77%, 
79%, 67% and 100%. At 8 weeks the percentage of patients alive was 100%, 53%, 69%, 64%, 
53% and 100%. There was no significant statistical difference in the age categories (p = 0.6 at 4 
weeks and at 8 weeks p = 0.45). Refer to table 9.2 below: 
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Table 9.2 Age Differences in Survival 
Alive after 4 weeks               
 Age <20 20-29 30-39 40-49 50-59 60-69 Total 
Alive   2 12 49 26 10 2 101 
Deceased 0 7 15 7 5 0 34 
Total 2 19 64 33 15 2 135 
Percentage 100 63.16 76.56 78.79 66.67 100 135 
Alive after 8 weeks               
 Age <20 20-29 30-39 40-49 50-59 60-69 Total 
Alive   2 10 44 21 8 2 87 
Deceased 0 9 20 12 7 0 48 
Total 2 19 64 33 15 2 135 
Percentage 100 52.63 68.75 63.64 53.33 100 135 
 
It was considered if the year of diagnosis would alter prognosis. There was no statistical difference 
found for survival over the different years (p = 0.55 at 4 weeks and p = 0.83 at 8 weeks). The 
survival rates per year are shown in table 9.3 below: 
Table 9.3 Year of Diagnosis and Differences in Survival 
Alive after 4 weeks                       
Year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total 
Alive   5 8 2 4 3 12 17 12 23 17 103 
Deceased 0 1 0 2 1 8 4 3 11 4 34 
Total 5 9 2 6 4 20 21 15 34 21 137 
                        
Alive after 8 weeks                       
Year 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Total 
Alive   3 7 2 4 3 12 14 12 19 13 89 
Deceased 2 2 0 2 1 8 7 3 15 8 48 
Total 5 9 2 6 4 20 21 15 34 21 137 
 
In terms of performance status, it appeared that a better performance status was associated with 
longer survival. At 4 Weeks, the percentage of patients alive were 87%, 84%, 67% and 41% for 
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performance status 1, 2, 3 and 4 respectively. At 8 weeks; these percentages were 78%, 76%, 32% 
and 32% respectively. The differences in both groups were statistically significantly different (p = 
0.00015 and 0.000251 respectively). Refer to table 9.4 below: 
Table 9.4 Performance Status and Differences in Survival 
Alive after 4 
weeks           
Alive after 8 
weeks           
Performance 
Status 1 2 3 4 Total 
Performance 
Status 1 2 3 4 Total 
Alive   40 38 14 9 101 Alive   36 34 10 7 87 
Deceased 6 7 7 13 33 Deceased 10 11 11 15 47 
Total 46 45 21 22 134 Total 46 45 21 22 134 
 
There was no significant difference in survival in patients with past or present Tuberculosis 
infection. At 4 weeks, 70% of patients with TB exposure were alive and 76% of patients without 
exposure were alive. This was slightly reversed in the 8 week group, 67% of patients exposed to 
TB were alive and 65% of patients without exposure were alive (p = 0.52 and p = 0.84 in the 4 and 
8 week groups respectively). Refer to table 9.5 below: 
Table 9.5 Tuberculosis (TB) Exposure and Differences in Survival 
Alive after 4 weeks       Alive after 8 weeks       
 Tb  No Tb Total  Tb  No Tb Total 
Alive 19 84 103 Alive 18 71 89 
Deceased 8 26 34 Deceased 9 39 48 
Percentage Alive 70.3 76.4 75.2 Percentage Alive 66.7 64.5 65 
Total 27 110 137 Total 27 110 137 
 
The presence of co-morbidities other than TB and HIV, did not confer a statistically significant 
difference in survival outcome. At 4 weeks, 68% of patients with co-morbidities were alive and 
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77% of patients without co-morbidities were alive (p = 0.36). At 8 weeks, 64% of patients with 
comorbidities were alive and 65% of patients without co-morbidities were alive (p = 0.91). Refer 
to table 9.6 below: 
Table 9.6 Presence of Co-morbidities and Survival Differences 
Alive at 4 weeks         Alive at 8 weeks       
Co-morbidity Yes No Total   Co-morbidity Yes No Total 
Alive    17 86 103   Alive    16 73 89 
Deceased 8 26 34   Deceased 9 39 48 
Percentage Alive 68 76.8 75.2  Percentage Alive 64 65.2 65 
Total 25 112 137   Total 25 112 137 
 
In the HIV infected population, being on cART conferred a statistically significant survival 
difference. The percentage of patients on cART who were alive at 4 weeks was 86%, and the 
percentage of patients not on cART alive at 4 weeks was 32% (p = 0.00). The patients on cART 
who were alive at 8 weeks was 76% and the patients not on cART alive at 8 weeks was 24% (p = 
0.00). Refer to table 9.7 below: 
Table 9.7 Survival Differences if Treated with cART 
Alive at 4 weeks     Alive at 8 weeks       
  On cART 
Not on 
cART Total   On cART 
Not on 
cART Total 
Alive   90 8 98 Alive   80 6 86 
Deceased 15 17 32 Deceased 25 19 44 
Percentage Alive 85.7 32 75.4 Percentage Alive 76.2 24 66.2 
Total 105 25 130 Total 105 25 130 
cART- Combination Anti-retroviral Therapy 
The presence of “B” symptoms was considered as a prognostic factor. At 4 weeks, 75% of patients 
with “B” symptoms were alive and 93% of patients without “B” symptoms were alive. At 8 weeks, 
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this was 65% and 80%, respectively. This difference was not of statistical significance (p = 0.12 
and p = 0.26 at 4 and 8 weeks respectively). Refer to table 9.8 below:  
Table 9.8 Presence of “B” Symptoms and Differences in Survival 
Alive at 4 weeks         Alive at 8 weeks       
 “B” symptoms Yes No Total    “B” symptoms Yes No Total 
Alive   83 14 97   Alive   72 12 84 
Deceased 27 1 28   Deceased 38 3 41 
Percentage Alive 75.5 93.3 77.6  Percentage Alive 65.5 80 67.2 
Total 110 15 125   Total 110 15 125 
 
In patients with disease of the Central Nervous System (CNS), the percentage alive at 4 weeks was 
82%, while 73% of those without CNS disease were alive at 4 weeks. At 8 weeks, 71% of patients 
with CNS disease were alive and 63% of those without CNS disease were alive (p = 0.29 and p = 
0.38 at 4 weeks and 8 weeks respectively). Refer to table 9.9 below: 
Table 9.9 Presence of CNS Disease and Survival Differences 
Alive at 4 weeks         Alive at 8 weeks       
CNS disease Yes No Total   CNS disease Yes No Total 
Alive 31 67 98   Alive 27 58 85 
Deceased 7 25 32   Deceased 11 34 45 
Percentage Alive 81.6 72.8 75.4  Percentage Alive 71.1 63 65.4 
Total 38 92 130   Total 38 92 130 
 
At 4 weeks, 78% of patients with bulk disease were alive, and 73% of patients without bulk disease 
were alive. At 8 weeks, 70% of patients with bulk disease were alive and 61% of patients without 
bulk disease were alive. (p =0.45 and p = 0.28 at 4 and 8 weeks respectively). Refer to table 9.10.  
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Table 9.10 Presence of Bulk Disease and Survival Differences 
Alive at 4 weeks         Alive at 8 weeks       
Bulk disease  Y N Total   Bulk disease Y N Total 
Alive   47 56 103   Alive   42 47 89 
Deceased 13 21 34   Deceased 18 30 48 
Percentage Alive 78.3 72.7 75.2  Percentage Alive 70 61 65 
Total 60 77 137   Total 60 77 137 
 
Survival Differences in relation to stage of disease are summarized in table 9.11 below: 
Table 9.11 Survival Differences According to Stage of Disease 
Alive at 4 weeks                   
Stage IA IB IIA IIB IIIA IIIB IVA IVB Total 
Alive   1 0 3 10 2 4 4 78 102 
Deceased 0 0 0 2 0 5 0 25 32 
Total 1 0 3 12 2 9 4 103 134 
Percentage Alive 100 0 100 83.33 100 44.4 100 75.728   
                    
Alive at 8 weeks                   
Stage  IA IB IIA IIB IIIA IIIB IVA IVB Total 
Alive   1 0 3 9 2 4 4 65 88 
Deceased 0 0 0 3 0 5 0 38 46 
Total 1 0 3 12 2 9 4 103 134 
Percentage Alive 100 0 100 75 100 44.4 100 63.107   
 
Stage related differences in survival were not shown to be statistically significant (p = 0.53 and p 
= 0.74 at 4 and 8 weeks respectively).  
At 4 weeks 76% of patients whose histology was in keeping with classical BL were alive, 
compared to 71% of patients with “intermediate” histology. At 8 weeks, this translated to 67% and 
53% (p = 0.64 and p = 0.27 at 4 weeks and 8 weeks respectively). Refer to table 9.12. 
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Table 9.12 Survival Differences based on Histological Category 
Alive at 4 weeks       Alive at 8 weeks       
Category Burkitt Intermediate Total Category Burkitt Intermediate Total 
Alive   91 12 103 Alive   80 9 89 
Deceased 29 5 34 Deceased 40 8 48 
Percentage Alive 75.8 70.6 75.2 Percentage Alive 66.7 52.9 65 
Total 120 17 137 Total 120 17 137 
 
In the HIV sero-positive population, CD4 counts were categorized into groups : >500, 350-499, 
200-349, 100-199, 50-99 and <50. After 4 weeks, the percentage of patients alive were 75%, 69%, 
83%, 74%, 87% and 75%, respectively (p = 0.84). At 8 weeks, the percentage of patients alive 
were 67%, 62%, 71%, 67%, 87% and 55%, respectively (p = 0.51). Refer to table 9.13 below:  
Table 9.13 CD4 Counts and Survival Differences 
Alive at 4 weeks               
CD4 count >500 350-499 200-349 100-199 50-99 <50 Total 
Alive   9 9 20 31 13 15 97 
Deceased 3 4 4 11 2 5 29 
Total 12 13 24 42 15 20 126 
                
Alive at 8 weeks               
CD4 count >500 350-499 200-349 100-199 50-99 <50 Total 
Alive   8 8 17 28 13 11 85 
Deceased 4 5 7 14 2 9 41 
Total 12 13 24 42 15 20 126 
 
In terms of survival differences based on the chemotherapeutic regimen used, 81% of patients who 
used a CHOP regimen were alive at 4 weeks, whereas 72% of patients on a CHOP regimen were 
alive at 8 weeks (p = 0.4 in both groups). Refer to table 9.14.  
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Table 9.14 CHOP use and Survival 
Alive at 4 weeks       
CHOP Yes No Total 
Alive 26 77 103 
Deceased 6 27 33 
Total 32 104 136 
Percentage 81.25 74.04   
        
Alive at 8 weeks       
CHOP Yes No Total 
Alive 23 66 89 
Deceased 9 38 47 
Total 32 104 136 
Percentage 71.88 63.46   
At 4 weeks, 85% of patients on a “Burkitt” protocol were alive, whereas 76% of patients were 
alive at 8 weeks. The “Burkitt” protocol was associated with a statistically significant survival 
advantage (p = 0.00). Refer to table 9.15:  
Table 9.15 Burkitt Protocol use and Survival 
Alive at 4 weeks       
Burkitt Protocol Yes No Total 
Alive 80 23 103 
Deceased 14 19 33 
Total 94 42 136 
Percentage 85.11 54.76   
        
Alive at 8 weeks       
Burkitt Protocol Yes No Total 
Alive 71 18 89 
Deceased 23 24 47 
Total 94 42 136 
Percentage 75.53 42.86   
In cases where Rituximab was used, 98% of patients were alive at both 4 and 8 weeks. This was 
statistically significant (p = 0.00). Refer to table 9.16. 
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Table 9.16 Rituximab use and Survival 
Alive at 4 weeks       
Rituximab Yes No Total 
Alive 49 54 103 
Deceased 1 32 33 
Total 50 86 136 
Percentage 98 62.79   
        
Alive at 8 weeks       
Rituximab Yes No Total 
Alive 49 40 89 
Deceased 1 46 47 
Total 50 86 136 
Percentage 98 46.51   
Table 9.17 below summarizes the statistical significance of all the above-mentioned prognostic 
factors. 
Table 9.17 Summary of Prognostic Indicators and Statistical Significance thereof 
Prognostic Factor 
p value considered at 4 
weeks 
p value considered at 8 
weeks 
Gender 0.07 0.14 
Age 0.60 0.45 
Year of Diagnosis 0.55 0.83 
Performance Status 0.00 0.00 
Tuberculosis 0.52 0.84 
Comorbidities 0.36 0.91 
cART use 0.00 0.00 
B' symptoms 0.12 0.26 
CNS disease 0.29 0.38 
Bulk Disease 0.45 0.28 
Stage 0.53 0.74 
Burkitt Vs. 'Intermediate' histology 0.64 0.27 
CHOP chemotherapy protocol 0.41 0.38 
Burkitt chemotherapy protocol 0.00 0.00 
Rituximab use 0.00 0.00 
cART- Combination Anti-retroviral Therapy; CNS- Central Nervous System 
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4.0 CHAPTER FOUR:  DISCUSSION 
4.1 Discussion 
The study entailed a retrospective review of Burkitt Lymphoma at CHBAH, over a ten year period 
01/01/2005 to 31/12/2014. A total of 137 patients with BL were evaluable for review during the 
study period. There were 75 females (54.7%) and 62 males (45.3%), with a female to male ratio 
of 1.2:1.  
The median age at presentation was 38 years. Females tended to present at a slightly younger age 
of 37 years compared to their male counterparts (40 years). The higher female to male ratio is 
likely to be a reflection of the high association of HIV and the female preponderance in such an 
HIV sero-positive population- approximately 20% of South African women in the “reproductive 
age group” are estimated to be HIV sero-positive, with a female to male ratio for new infections 
of 1.5:1.33 
There is a clear trend of increasing incidence of BL over the past ten years, 26 cases (19%) of BL 
were diagnosed in the first five years whereas 111 cases (81%) were diagnosed in the latter five 
years. Once again, this may reflect the ongoing burden of the HIV pandemic and the continuing 
contribution of HIV to the increasing numbers of NHL patients seen at CHBAH.34 The increasing 
incidence of BL may also be due to more awareness of this entity by clinicians and improved 
subtyping of lymphomas by pathologists, given the broader array of immunophenotyping, 
cytogenetics and other molecular methods to more accurately define the subtypes of NHL.  
An interesting observation is the higher rate of admission of patients in the spring and summer 
seasons (58.4%), compared to autumn and winter (41.6%). This may be a coincidental observation, 
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as viral infections which may precipitate an underlying disease process are more likely to be 
encountered in the colder months.  
A worrying finding in this study is the lag phase between a tissue diagnosis and referral to the 
Clinical Haematology Unit, for definitive treatment. The average referral time was two weeks- 
which is somewhat delayed considering that the doubling time of BL is thought to be less than 24 
hours. 
It is also important to take into account delays in actually making a histological diagnosis. 
Although not included in the analysis of this study, while going through the various files it became 
apparent that there are clear delays in trying to secure a diagnostic biopsy in BL patients.  Often 
patients are required to have a Fine Needle Aspiration (FNA) done before a definitive histological 
biopsy (incision or excision) is performed. 
It was also evident following review of the files that patients presented late with more overt 
symptoms and signs of disease. At times, there was a delay in referral to a tertiary centre, where a 
definitive diagnosis could be made and therapy promptly initiated. Further delays may also occur 
where the result of the biopsy is not accessed timeously by the investigating doctor, resulting in 
unnecessary delays in initiating therapy. This is compounded by the fact that a complete work up 
may still need to be done once the patient is referred to the haematologists (including a CT scan, 
bone marrow biopsy, etc.) 
At presentation, 91 patients (66.4%) had a performance status (PS) of 1 or 2, while 43 patients 
(31.4%) had a PS of 3 or 4. The favourable PS (≤ 2) in the majority of patients may be due to the 
fact that most of our study population were young adults with few or no comorbidities.  
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In terms of the clinical presentation, lymphadenopathy and the presence of a jaw mass, were the 
most frequently encountered manifestations. Extra-nodal disease was also commonly encountered, 
based on the often widespread nature of the disease and the associated HIV sero-positivity. 
Bulk disease was encountered in 44% of the patients and involvement of the Central Nervous 
System (CNS) was seen in 28% of the patients at presentation.  
About half the study population had evidence of bone marrow infiltration or presented with an 
acute leukaemia. Seventy six patients (55.5%) had stage IVB disease at presentation. 
All these clinical features seem to imply that patients presented at an advanced stage of disease. 
This “advanced” presentation, with the existence of CNS manifestations or bulk disease, or 
presenting in a leukaemic phase may be secondary to the highly proliferative nature of BL itself. 
However, it seems logical to infer that delays in diagnosis, staging and referral of patients for 
management in addition to the intrinsic nature of the disease, are both contributing to the advanced 
nature of disease manifestations at the outset. 
As mentioned above and in the literature review, it is postulated that a relatively high CD4 count 
may be necessary in order to develop BL. In this study, the average CD4 count was 217/ul, with 
more than one third of the study population having a CD4 count of > 200/ul. These findings 
reinforce the above postulated theory, and may be a reflection of a relatively better immune status 
in patients with BL (as compared to DLBCL). 
The histological features found in our patients are in keeping with what is currently described in 
the literature. Most diagnoses were made on bone marrow biopsies, or biopsies of the nodal or 
extra-nodal masses. These predominantly showed a diffuse pattern of infiltration by intermediate 
sized cells. A high proliferation index was demonstrated, with a mean Ki-67 of 97%. The cells 
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were positive for CD20 (86.9%) and CD10 (81%) as well as for BCL6 in 66% of patients. MUM1 
and BCL2 were positive in 30% and 27%, respectively.  
The most common chromosomal abnormality described in our patient population was the t(8;14) 
translocation, which was seen in 42% of the patients. This was followed by the c-myc 
rearrangement, at 10%. One patient (0.7%) demonstrated a t(8;2) translocation. The t(8;22) 
translocation was not observed. These findings serve to reinforce the causal link between 
abnormalities of the c-myc oncogene on chromosome 8 and oncogenesis in BL.  
Morbidity and mortality were shown to be related to both the disease itself; and the toxic nature of 
the therapy.  
Patients with malignancy, and a degree of immobility have historically been a high risk group for 
the development of venous thromboembolism. However, in patients who have bone marrow 
infiltration by lymphoma or have bone marrow suppression secondary to chemotherapy, there is a 
resultant higher risk of bleeding, mainly secondary to thrombocytopenia. This latter concept may 
be the reason that thromboprophylaxis does not appear to have been routinely utilized in all the 
patients.  
In this study, venous thromboembolism (VTED) was more common (6.6%), than bleeding 
manifestations (2%), and thromboprophylaxis with low molecular weight heparin was not 
routinely used, but should always be a therapeutic consideration, in appropriate patients. 
Additionally, one needs to guard against the increased risk of bleeding in patients with 
thromboprophylaxis, who may develop thrombocytopenia during the course of their disease. 
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Similarly, as a result of bone marrow suppression or infiltration, neutropaenic episodes are an 
observed complication (6.1%). After disease progression, sepsis, including neutropaenic sepsis 
(36.3%), was the main contributor to morbidity and mortality.  
Neutropaenic measures, including the use of empiric antibiotics and growth factors where 
necessary for severe neutropaenia is a standard of care to prevent the consequences of severe 
neutropaenia. 
Involvement of the CNS has been noted to be a common occurrence. This includes not only 
leptomeningeal involvement, but also other CNS manifestations including cranial nerve palsies, 
spinal cord compression and neuropathies secondary to the compressive effects of bulk tumours. 
It is essential that intra-thecal chemotherapy should be part of the routine management of this 
lymphoma, considering its high propensity for involvement of the CNS. 
Furthermore, radiation needs to be considered early in patients with compressive symptoms before 
irreversible damage occurs to nerve tissue. It should also be an early consideration in patients 
whose masses are enlarging despite adequate chemotherapy or where disease appears to be 
resistant to other therapeutic modalities.  
Renal dysfunction is another commonly observed complication.  Adequate hydration of patients 
is essential, especially when patients present with increased insensible losses and inadequate intake 
of fluids, compounded by renal impairment.  
The use of allopurinol, to prevent or treat hyperuricaemia is essential in all patients. Monitoring 
and early management of patients with Tumour Lysis Syndrome is of paramount importance in 
BL. It is not always possible and feasible to offer dialysis to patients in our resource constrained 
setting, but where it is needed, it should be instituted early. 
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Tumour Lysis Syndrome (TLS) should be actively and routinely sought in all patients with BL, 
particularly following chemotherapy. Judicious monitoring of patients and early and appropriate 
fluid and electrolyte management, and where necessary, early recourse to dialysis in the patients 
with worsening renal function despite adequate supportive measures, has a favorable impact on 
the prognosis of patients with TLS.  
Being an aggressive tumour, with a high doubling time, a number of patients tend to show a rapid 
response to chemotherapy. Complete remission is possible, with 15% of patients in this series 
being in remission at their last observable date of review. Whether this is sustainable is a question 
which needs to be looked at further. A fine balance between remission and toxicity of therapy 
needs to be struck. 
Unfortunately, a large number of study participants demised. Twenty five percent (25%) of the 
patients survived less than 4 weeks; and 35% survived less than 8 weeks. The longest survivor is 
alive more than 7 years after diagnosis. The overall poor survival is highly significant. If early 
deaths can be impacted upon and reduced significantly, the survival of patients will be improved 
and increased to more acceptable levels.  
The main contributors to mortality were disease progression, sepsis, renal failure, venous 
thromboembolism and tumour lysis syndrome. Of note is that the last 4 of these contributors are 
potentially preventable.  
A high index of suspicion of early infection and better and improved infection control measures 
(such as increased access to isolation and barrier nursing), as well as empiric and earlier use of 
antibiotics (prophylactic), and growth factors (where indicated) are warranted in our setting, to 
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reduce the burden of sepsis and the morbidity and mortality associated with infection and 
neutropaenic sepsis.  
Venous thromboembolism is another contributor to morbidity and mortality. As mentioned earlier, 
it is a dilemma to routinely anticoagulate high risk patients prophylactically, as these patients have 
an increased risk of bleeding. However, in hospitalized patients where close observation and 
regular monitoring of the patient is possible, this may be feasible.   
There seems to be “no right answer” when considering thromboprophylaxis, and patients need to 
be individualized, based on their risk profile and safety concerns. Other, less potentially hazardous 
strategies should always be considered and include: i) maintaining adequate hydration, ii) early 
mobilization and use of calf compression pumps in patients who are immobile, as well as the use 
of allied services such as physiotherapy, who may assist in early mobilization of the patients. 
The results of the full blood count seem to follow an expected pattern. It is noteworthy that a few 
patients were leucopaenic (12.4%) on admission, as well as neutropaenic (11%). Neutropaenia is 
a risk factor for sepsis and adds to the risk of sepsis in immunocompromised patients with HIV, 
malignancy and chemotherapy, including use of corticosteroids. 
Our female patients tended to have higher rates of anaemia than their male counter parts. This may 
be due to reasons other than the manifestations of the malignancy. Most of patients were in the so 
called “reproductive age group’. It is possible that menstrual losses may have contributed to higher 
rates of iron deficiency anaemia in females.  
Regarding the biochemistry results, we would have expected the leukaemic subgroup of patients 
to have the most observable abnormalities due to the highest rate of cell turnover. Indeed, it was 
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noted that the urea and creatinine levels, as well as the Beta-2 microglobulin and uric acid, were 
increased the most, pro rata in the leukaemic subset. LDH levels were increased overall.  
The leukaemic group of patients also had lower albumin levels. Perhaps this indicates a more 
severely ill group of patients, with a negative acute phase reactant response. 
There were multiple variables which were considered as theoretical prognostic indicators. 
Although the majority of results observed were not statistically significant, it does highlight some 
potential trends.  
It would appear that female patients survive longer than their male counterparts. This may be due 
to differences in health seeking behaviour known to occur in this country, whereby females are 
more likely to present with medical complaints early. This observed difference was not statistically 
significant. 
There was no discernable statistical difference between advancing age and survival outcomes in 
our patient population. 
Performance status was the only statistically significant demographic prognostic indicator, with 
an advanced performance status (≥ 2), conferring a less favourable outcome.  
Exposure to Tuberculosis did not seem to confer a survival advantage or disadvantage. The 
presence of TB is likely to be more closely related to the underlying HIV rather than the 
malignancy. 
Patients with HIV infection who were on cART demonstrated statistically significant improved 
outcomes compared to patients not on cART. Improved outcomes were similarly documented in 
patients without “B” symptoms. These findings were however, not statistically significant. 
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Somewhat counterintuitively, the presence of bulk disease and involvement of the Central Nervous 
System seemed to confer a better survival (though not statistically significant). A likely 
explanation is that such patients may have been treated more aggressively and with a multi-
modality approach, such as involved field radiotherapy in the case of bulk disease, or intra-thecal 
chemotherapy, +/- radiotherapy in the case of CNS disease. In general, all patients with BL should 
receive intra-thecal (IT) chemotherapy (prophylaxis), irrespective of leptomeningeal disease 
involvement, or therapeutic IT, in the case of documented CNS disease, as the rate of CNS disease 
is high in patients with the BL spectrum of disorders. 
In this study, there was no apparent statistically significant link between advanced stage of disease 
and adverse outcomes. This is likely a reflection of the aggressive and symptomatic nature of the 
disease warranting medical attention sooner in patients harboring the disease.  
Patients whose histology was most in keeping with BL tended to fair better than the “intermediate” 
category. This may be due to a more aggressive tumour in the case of “intermediate” histology, or 
this ‘intermediate’ category may be an entirely different biological entity, for which the most 
appropriate therapy is still not defined.  
There was no adverse prognostic significance regarding the CD4 count level. Again, the CD4 
count may be more of a reflection of the underlying HIV rather than the BL. 
In terms of chemotherapeutic regimens being used, a statistically significant survival benefit was 
evident for patients who were treated with the so called “Burkitt” protocol (see Appendix III), as 
compared to patients treated with a CHOP protocol. Furthermore, the addition of Rituximab 
demonstrated a statistically significant improvement in survival outcomes. 
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The “Burkitt” protocol’ consists of rapid recycling of potent chemotherapy drugs together with the 
routine use of intra-thecal chemoprophylaxis. Better outcomes with this protocol serves as further 
evidence to support the use of this protocol routinely with potential optimization of the existing 
backbone and schedule of treatment. 
4.2 Limitations of the Study 
As the study was retrospective in nature, it was subject to the following limitations:  
 Completeness of records: Many of the patients’ files were incomplete. A fair amount of 
data was missing especially with regard to histology and radiological information. Some 
patients had missing clinical data and treatment details. This may have contributed to minor 
inaccuracies in some of the data that has been presented. Where data was missing in patient 
files regarding histology, a search of the laboratory database ensued and this too was not 
always complete. Missing data from before 2012 was particularly difficult to obtain.  
 Tumour misclassification: This may be true with respect to the “intermediate” subtype, 
now referred to as High Grade B-cell NHL, not otherwise specified (HGBL, NOS). The 
information on all such patients was reviewed and where key data was missing, these 
patients were excluded from the study. 
 Lost to follow up: As many as 24 patients were lost to follow up. Whether they succumbed 
to disease at home or whether they are still alive is unknown. More stringent follow up of 
patients is required in order to minimize the number of patients lost to follow up. The 
reasons for this problem, whether socioeconomic or otherwise, will also need to be 
explored in the future.  
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5.0 CONCLUSION 
Based on the findings of this study, BL is an increasing entity in the era of the HIV pandemic, as 
evidenced by the increasing numbers over time, at Chris Hani Baragwanath Academic Hospital. 
This may be an indirect reflection of an increased incidence in South Africa as a whole. Several 
factors may have contributed to this increase, including the ongoing high burden of HIV infection 
as indicated above, the increased longevity of patients with HIV following the use of cART, a 
higher index of suspicion and better and improved techniques of establishing a diagnosis. 
Burkitt Lymphoma is an aggressive, rapidly proliferative malignancy, with a propensity for 
Central Nervous System (CNS) involvement. It most often presents with lymphadenopathy, 
involving peripheral and central sites. Bulky disease and extra-nodal involvement are common. 
Adult patients at CHBAH tend to manifest with the HIV-associated variant (or immunodeficiency 
variant) of BL, as opposed to the endemic or sporadic variety. Almost all of the patients (98.5%) 
in this study, and with this variant, are HIV sero-positive.  
Constitutional symptoms (“B” Symptoms) are frequently encountered in our patients. Most 
patients present at a young age (mean age – 38 years), with few comorbidities and a more 
favourable performance status. However, despite a favourable performance status, patients tended 
to have an advanced stage of disease at presentation. This may be due to the rapidly growing nature 
of the tumour itself, or to various delays in clinical presentation and establishing a definitive 
histological diagnosis. 
The histology of this lymphoma typically shows a diffuse pattern of infiltration by intermediate 
sized cells, which express CD20 and CD10. BCL-6 is usually also positive. A rapid proliferative 
index is present, with a Ki-67 proliferation index in excess of 95%. 
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The most frequent genetic abnormalities demonstrated were the t(8;14), followed by the c-myc 
rearrangement. Other abnormalities of the c-myc oncogene on chromosome 8 were demonstrated 
less frequently. 
In addition to supportive care, therapeutic measures tend to be the intensive, incorporated in the 
so called “Burkitt” protocol’. Patients in the earlier part of the study received a CHOP regimen. A 
multimodality approach was employed and included intra-thecal chemotherapy as well as 
radiotherapy, where indicated.  
Chemotherapy side effects were common, with sepsis being the most frequent problem 
encountered. 
The overall outcome (survival) of the patients was generally poor. The greatest contributors to 
mortality were disease progression, sepsis, neutropaenia, renal dysfunction/TLS and 
thromboembolic disease. Many of these contributing factors are potentially avoidable and 
treatable, with greater infection control measures/protocols, judicious use of antibiotic therapy, 
attention to fluid and electrolyte management, and early recourse to dialysis, where indicated, and 
a high index of suspicion of thrombotic events and early access to thromboprophylaxis where 
necessary and feasible. 
Prognostic factors were analysed. Females tend to survive longer than their male counterparts. 
Tuberculosis infection conferred a worse outcome, as did the presence of other medical co-
morbidities. Being on cART therapy improved overall survival. The absence of “B” symptoms 
was considered favourable. Stage of disease was not consistently associated with adverse or poorer 
survival. CD4 counts did not seem to affect survival outcomes. Burkitt Lymphoma in its classical 
form had a more favourable outcome than the “intermediate” form of disease.  
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Somewhat counterintuitively, the presence of CNS or bulk disease led to better outcomes. The 
only demographic adverse prognostic factor of statistical significance that was identified is 
performance status; with a more favourable performance status conferring a more favourable 
outcome. 
Leukaemic patients had the worst outcomes, manifesting with higher levels of uric acid, LDH, 
Beta-2 microglobulin and renal dysfunction.  
In terms of chemotherapy a “Burkitt” protocol seemed to confer a more favourable outcome 
compared to a CHOP chemotherapeutic regimen with a statistically significant survival difference 
being observed in patients treated with a “Burkitt” protocol’. The addition of Rituximab confers 
survival benefit.  
In the South African context, BL is the second most common subtype of NHL, after DLBCL.   
With a high index of suspicion and expedited referral, timeous workup and staging, better attention 
to and prevention of complications and an intensive multimodality approach to therapy, early and 
ongoing use of cART in HIV sero-positive individuals, the outlook is likely to be much brighter, 
with higher sustained response rates and improved long term outcomes, in this aggressive, highly 
proliferative and devastating disease. 
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Appendix I 
Data Collection Sheet 
Demographics 
Study Number  
Gender Male                                    Female  
Age:  
Date of diagnosis DD:       MM:       YYYY:             
Date of haematology referral DD:       MM:       YYYY: 
Performance status (initial) 0          1          2          3          4          5     
Race B        W         C A Other: 
Comorbidities HIV  TB  Other  
Details of other comorbidities if present   
  
  
 
History 
Symptom Yes No  
Fever    
Loss of weight   Amount (kg):  
Time (weeks-months):  
Night sweats    
Fatigue    
Bleeding   Site: 
Bone pain   Site: 
If 
HIVseropos. 
  CD4: 
Date diagnosed: 
 
If seropos, is 
patient on 
cART? 
 
 
 Date Commenced: 
 
Type: 
 
 
Examination 
Sign Yes No Details/Size (cm): 
Pallor    
 
 
Jaundice    
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Lymphadenopathy 
(peripheral): 
I- Cervical 
Submental            □ 
Submandibular   □ 
Ant triangle         □ 
Post triangle        □ 
Pre-auric             □ 
Post-auric            □ 
Supra-clavic.        □ 
Occipital              □ 
  
 
 
II- Axillary 
 
   
 
 
III- Epitrochlear 
 
   
IV- Inguinal 
 
   
V- Femoral  
 
  
Lymphadenopathy 
(Central): 
I- Waldeyer’s 
Ring 
   
II- Intra-thoracic 
 
SVC syndrome     □ 
D’espians sign      □ 
Pemberton’s sign □ 
  
III- Intra-
abdominal 
 
Masses                  □ 
Ascites                  □ 
Leg swelling         □ 
Scrotum/testes     □ 
  
Other lesions/ Masses 
(I.e. extra-nodal disease) 
 
 
 
 
Site: 
  
 
 
Hepatomegaly    
Splenomegaly    
Bleeding Petechiae              □ 
Purpura                □ 
Ecchymoses          □ 
Mucosal                □ 
  
Neurological deficit 
 
 
   
 
Other relevant clinical 
finding, if present 
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Chest X Ray:  
Normal:       Abnormal:   
Abnormality Detail 
  
  
  
 
CT scan 
Normal:       Abnormal: 
Abnormality Detail 
  
  
  
  
  
 
Bone Marrow Infiltration: 
Yes:        No: 
Leukaemic Phase: 
Yes:        No: 
Stage: 
Clinical:       Radiological:  
Histology 
Site of specimen: 
Pattern of infiltration Diffuse □   Focal/nodular □    Interstitial □ 
Cell size (tick all blocks that apply) 
                         Predominant population:  
Small □  Intermediate □  Large □  Mixed □ 
CD 20 Positive  □                      Negative  □ 
CD 10 Positive  □                      Negative  □ 
MUM 1 Positive  □                      Negative  □ 
BCL 6 Positive  □                      Negative  □ 
BCL 2 Positive  □                      Negative  □ 
Ki67 Positive  □  %:               Negative  □       
Cytogenetics (specify translocation) t(8;14)  □    t(8;2)  □    t(8;22)  □ 
c-myc rearrangement  □ 
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Treatment 
Date of first treatment: 
Specific #cycles/doses/duration 
CHOP/R-CHOP  
 
 
 
 
 
 
 
 
Burkitt Protocol  
 
 
 
 
 
 
 
 
 
Intra-thecal 
chemotherapy 
 
 
 
 
 
 
Radiation 
 
 
 
 
 
 
 
Other Protocols 
 
 
 
 
 
 
Supportive  
Allopurinol 
 
 
 
Analgesia 
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Thromboprophylaxis 
 
 
Antibiotics (state if 
prophylactic or 
therapeutic) 
 
 
Other (e.g. dialysis, 
blood products, 
Neupogen) 
 
 
 
Complications:  
(State if tumour lysis syndrome (TLS), CNS disease, profound myelosuppression (grade 3+), 
infections, bleeding or other significant complications) 
Date Complication Management 
  
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Response 
 After initial therapy Interim As at last date seen 
Date    
 
Complete Response    
 
Partial Response    
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Disease Progression 
(Provide details) 
   
 
Outcome 
Date:  
Alive                               Deceased                                Lost to follow up  
If deceased: 
Cause/s of death: 
 
 
Survival time (date of death – date of diagnosis) in months:  
 
If lost to follow up:       
Date last seen: 
Status of disease at last visit (e.g. remission, relapse):                    
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Appendix III 
Burkitt Chemotherapy Protocol 
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